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A B B R E V I A T I O N S    A N D   D E F I N I T I O N S 
Ahr Arylhydrocarbon receptor 
ANOVA Analysis of variance 
ARNT Ahr nuclear translocator 
ATP Adenosine triphosphate 
AUC0-t Area under the concentration-time curve from 0 to t hours 
BCRP Breast cancer resistance protein 
CAR Constitutive androstane receptor 
CI Confidence interval 
CL Clearance 
CLint Intrinsic clearance 
Cmax Peak concentration  
COMT Catechol O-methyltransferase 
CV Coefficient of variation 
CYP Cytochrome P450 
DM Diabetes mellitus 
DNA Deoxyribonucleic acid; cDNA = complementary DNA 
EMEA The European Agency for the Evaluation of Medicinal Products 
ER Endoplasmic reticulum 
FAD Flavin adenine dinucleotide 
FMO Flavin mono-oxygenase 
fu Unbound fraction of drug 
GST Glutathione transferase 
HbA1c Glycosylated haemoglobin 
HDL High-density lipoprotein 
HLM Human liver microsomes 
HNMT Histamine N-methyltransferase 
HPLC High-performance liquid chromatography 
IC50 Inhibitor concentration causing 50% inhibition of the activity 
ISEF Intersystem extrapolating factor 
kel Elimination-rate constant 
Ki Inhibition constant for competitive inhibition 
KI Inhibitor concentration where inactivation rate of metabolism-
dependent inhibition is 50% of maximum 
Kinact Rate of enzyme inactivation for metabolism-dependent inhibition 
Km Michaelis-Menten kinetic constant 
LC-MS-MS Liquid chromatography-tandem mass spectrometry 
LDL Low-density lipoprotein 
MAO Monoamine oxidase 
MRP Multidrug-resistance-related protein 
m/z Mass-to-charge ratio 
NADPH Nicotinamide adenine dinucleotide phosphate 
NAT Arylamine N-acetyltransferase 






OAT Organic anion transporter 
OATP Organic anion transporting polypeptide 
OCT  Organic cation transporter 
PAH Polycyclic hydrocarbon 
PEPT Peptide transporter 
PON Paraoxonase 
PPAR Peroxisome proliferator-activated receptor 
PXR Pregnane X receptor 
RAF Relative activity factor 
rhCYP Recombinantly expressed human CYP enzyme 
RNA Ribonucleic acid; mRNA = messenger RNA 
RXR Retinoid X receptor 
SD Standard deviation 
SNP Single nucleotide polymorphism 
SULT Sulfotransferase 
t½ Elimination half-life 
tmax Time to peak concentration 
TPMT  Thiopurine methyltransferase 
UGT UDP-glucuronosyltransferase 
Vd Volume of distribution 
Vmax Maximum reaction velocity 
XRE Xenobiotic response element 
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A B S T R A C T 
INTRODUCTION Repaglinide is a short-acting oral insulin secretagogue, used to 
reduce postprandial hyperglycaemia in type 2 diabetic patients. Repaglinide is 
extensively metabolised, and due to considerable first-pass metabolism its oral 
bioavailability is about 60%. Repaglinide is mainly eliminated by excretion into 
bile as inactive metabolites. In previous studies, the cytochrome P450 (CYP) 3A4 
inhibitors itraconazole and clarithromycin have moderately increased the area 
under the concentration-time curve (AUC) of repaglinide. Gemfibrozil, a CYP2C8 
inhibitor, has greatly increased repaglinide AUC, enhancing and prolonging its 
blood glucose-lowering effect. Rifampicin has decreased the AUC and effects of 
repaglinide.  
AIMS The aims of this work were to investigate the contribution of CYP2C8 and 
CYP3A4 to the metabolism of repaglinide, and to study other potential drug 
interactions affecting the pharmacokinetics of repaglinide, and the mechanisms 
of observed interactions.  
METHODS The metabolism of repaglinide was studied in vitro using recombinant 
human CYP enzymes and pooled human liver microsomes (HLM). The effect of 
trimethoprim, cyclosporine, bezafibrate, fenofibrate, gemfibrozil, and rifampicin 
on the metabolism of repaglinide, and the effect of fibrates and rifampicin on the 
activity of CYP2C8 and CYP3A4 were investigated in vitro.  
Randomised, placebo-controlled cross-over studies were carried out in healthy 
human volunteers to investigate the effect of bezafibrate, fenofibrate, 
trimethoprim, cyclosporine, telithromycin, montelukast and pioglitazone on the 
pharmacokinetics and pharmacodynamics of repaglinide. Pretreatment with 
clinically relevant doses of the study drug or placebo was followed by a single 
dose of repaglinide, after which blood and urine samples were collected to 
determine pharmacokinetic and pharmacodynamic parameters. 
RESULTS In vitro, the contribution of CYP2C8 was similar to that of CYP3A4 in the 
metabolism of repaglinide (< 2 µM). Bezafibrate, fenofibrate, gemfibrozil, and 
rifampicin moderately inhibited CYP2C8 (Ki 9.7 µM, 30.4 µM, 92.6 µM, and 30.2 
µM, respectively) and repaglinide metabolism (IC50 37.7 µM, 111 µM, 164 µM, 
and  13.7 µM, respectively), but only rifampicin inhibited CYP3A4 (Ki  18.5 µM) in 
vitro. 
Bezafibrate, fenofibrate, montelukast, and pioglitazone had no effect on the 
pharmacokinetics and pharmacodynamics of repaglinide in vivo. The CYP2C8 
inhibitor trimethoprim inhibited repaglinide metabolism by HLM in vitro (IC50 129 
µM) and increased repaglinide AUC by 61% in vivo (P < .001). The CYP3A4 
inhibitor telithromycin increased repaglinide AUC 1.8-fold (P < .001) and 
enhanced its blood glucose-lowering effect in vivo. Cyclosporine inhibited the 
CYP3A4-mediated (but not CYP2C8-mediated) metabolism of repaglinide in vitro 
and increased repaglinide AUC 2.4-fold in vivo (P < .001). The effect of 
cyclosporine on repaglinide AUC in vivo correlated with the SLCO1B1 (encoding 




CONCLUSIONS The relative contributions of CYP2C8 and CYP3A4 to the 
metabolism of repaglinide are similar in vitro, when therapeutic repaglinide 
concentrations are used. In vivo, repaglinide AUC was considerably increased by 
inhibition of both CYP2C8 (by trimethoprim) and CYP3A4 (by telithromycin). 
Cyclosporine raised repaglinide AUC even higher, probably by inhibiting the 
CYP3A4-mediated biotransformation and OATP1B1-mediated hepatic uptake of 
repaglinide. Bezafibrate, fenofibrate, montelukast, and pioglitazone had no effect 
on the pharmacokinetics of repaglinide, suggesting that they do not significantly 
inhibit CYP2C8 or CYP3A4 in vivo.  
Coadministration of drugs that inhibit CYP2C8, CYP3A4 or OATP1B1 may increase 
the plasma concentrations and blood glucose-lowering effect of repaglinide, 
requiring closer monitoring of blood glucose concentrations to avoid 
hypoglycaemia, and adjustment of repaglinide dosage as necessary. 
 





I N T R O D U C T I O N 
Repaglinide is a short-acting blood glucose-lowering drug aimed to be taken with 
meals in the treatment of type 2 diabetic patients.1 Repaglinide stimulates 
insulin release from the pancreas,2 and it can be used as monotherapy, or in 
combination with e.g. metformin or a glitazone.2-4 Repaglinide is extensively 
metabolised by the cytochrome P450 (CYP) system to inactive metabolites, and 
the main route of excretion of repaglinide and its metabolites is via bile into 
faeces.5   
CYP enzymes play a central role in the metabolism of drugs, and inhibition or 
induction of these enzymes can alter the plasma concentrations and effects of 
their substrate drugs.6 CYP2C8 and CYP3A4 participate in the biotransformation 
of repaglinide, but their contributions at clinically relevant repaglinide 
concentrations in vitro have been unclear.7 Clarithromycin8 and itraconazole9 
(inhibitors of CYP3A4) have increased repaglinide area under the concentration-
time curve (AUC) by about 40%. Gemfibrozil has caused the largest increases in 
the plasma concentrations of repaglinide, an approximately 8-fold increase in the 
AUC, and has strongly enhanced its blood glucose-lowering effects.9 Rifampicin 
(inducer of CYP enzymes and transporters) has decreased the plasma 
concentrations and effects of repaglinide.10-12  
When this work was initiated, the mechanism of the drastic interaction between 
gemfibrozil and repaglinide was unclear. Gemfibrozil had been shown to increase 
the plasma concentrations of the CYP2C8 substrate cerivastatin,13 but the 
inhibitory effect of gemfibrozil on CYP2C8 in vitro had been only moderate.14  
Furthermore, gemfibrozil does not inhibit CYP3A4,15 and it seemed unlikely that 
moderate inhibition of only one of the two CYPs participating in the metabolism 
of repaglinide would explain the observed interaction.9 In addition, the cause of 
the variation in the observed effects of rifampicin on repaglinide 
pharmacokinetics10-12 was not known, and the effect of transporter inhibition on 
repaglinide pharmacokinetics had not been studied.  
The aim of this work was to investigate repaglinide metabolism in vitro using 
therapeutic repaglinide concentrations, particularly the relative contributions of 
CYP2C8 and CYP3A4. The susceptibility of repaglinide to other pharmacokinetic 
interactions was studied in humans. The drugs studied with repaglinide in vivo 
included fibrates (bezafibrate and fenofibrate), selective in vitro inhibitors of 
CYP2C8 (trimethoprim and montelukast),16,17 and the CYP3A4 inhibitor 
telithromycin.18 The effect of pioglitazone (inhibitor of CYP2C8 and CYP3A4 in 
vitro)19 on repaglinide was also studied to determine whether their synergistic 
effect, observed in diabetic patients,20 was caused by inhibition of repaglinide 
metabolism. The effect of cyclosporine, an inhibitor of CYP3A4, organic anion 
transporting polypeptide 1 (OATP1B1), and P-glycoprotein,21-24 on repaglinide 
was also investigated. 
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R E V I E W   O F   T H E   L I T E R A T U R E  
1 Drug interactions 
The pharmacologic effects of drugs are based on interaction of the unbound drug 
with their targets (enzymes, receptors) in their target tissues.25 Route of 
administration, dose, drug pharmacokinetics, the distribution to the site of  
action, the concentration-response relationship, and drug removal 
(redistribution, elimination) determine the rapidity and duration of 
pharmacological effect.25,26 Drug exposure is usually described by the peak drug 
concentration (Cmax) and AUC, and drug elimination by half-life (t½) and 
clearance (CL).25   
With the increasing availability of new drugs, the concurrent use of multiple 
medications is very common, particularly in elderly patients. Drug interactions 
are an important aspect of clinical drug application in patients receiving multiple 
drug regimens. In drug interactions, the combined effects of interacting drugs 
are greater (or less) than the arithmetic sum of their individual actions, usually 
due to pharmacokinetic or pharmacodynamic interference. The underlying 
mechanism of pharmacokinetic drug interactions is usually a change in the 
systemic clearance or distribution of one drug by another drug. In 
pharmacodynamic drug interactions the coadministered drugs have overlapping 
pharmacologic mechanisms or similar target systems. Drug interactions can lead 
to therapeutic failure (due to lack of effect) or drug overdose (exaggerated 
pharmacological response and/or drug toxicity), but drug interactions may also 
be modest and lack clinical significance.27,28  
When any two drugs are administered together, the risk for interaction has been 
reported to be 6%,29,30 increasing exponentially with the number of 
coadministered drugs.31-33 Up to 10% of all hospital admissions in the elderly 
have been reported to be drug-related,29 with fatal adverse drug effects being 
the 6th leading cause of death in the USA.34 Of all adverse drug reactions, up to 
20 to 30% are assumed to be caused by drug interactions.29,35,36 In the 
pharmacological therapy of type 2 diabetes, drugs with additive glucose-lowering 
effects are used to gain better glycemic control, but such combinations carry a 
higher risk of hypoglycaemic episodes.37  
1.1 Pharmacokinetic drug interactions 
In pharmacokinetic drug interactions, e.g. the absorption, distribution, protein 
binding, metabolism or excretion of a drug is altered by a coadministered drug. 
The concentrations of the victim drug are altered, and if the change is great 
enough, the clinical effect of the drug may also be changed.38  
Reversible inhibition of cytochrome P450 (CYP) enzymes is probably the most 
common cause of pharmacokinetic interactions, because CYPs have a pivotal role 
in the metabolism majority of drugs. Whether a reversible inhibitor will cause a 
clinically significant impairment of drug metabolism, will depend on the affinities 
of the substrate (Km) and inhibitor (Ki) to the drug-metabolising enzyme, and the 
concentration of each drug at the relevant site of the biological process (affected 
by dose, distribution, protein binding, etc.).38,39  





A pharmacokinetic interaction caused by direct competitive inhibition of drug 
metabolism (or transport) starts as the target protein is exposed to the inhibitor, 
and ends when the inhibitor is no longer present. The onset and offset of effect 
are rapid, and no prior exposure to the inhibitor is needed. Inhibitor 
concentration at the target site and its inhibitory potency determine the 
magnitude of interaction. The effect of induction of drug metabolism (or 
transport) is seen more slowly, and depends also on the duration of exposure to 
the inducer. Onset and offset of the inducing effect are slow, and 
pharmacokinetics of the victim drug can remain altered even if the inducer is no 
longer present.27,38,39   
Orally administered drugs that have a low bioavailability due to presystemic 
metabolism are particularly susceptible to inhibitory interactions. Potent 
inhibition of their metabolism can cause drastic increases in their bioavailability 
and peak plasma concentrations, greatly affecting their clinical effects and 
adverse reactions. For drugs with high bioavailability that are also eliminated by 
metabolism, potent inhibition of their metabolism probably leads to prolonged  
elimination half-life and effects, but after a single dose of the victim drug, the 
peak concentrations are unlikely to be significantly affected.27,38,39 
1.2 Pharmacodynamic drug interactions  
In pharmacodynamic interactions the effects of one drug are changed by the 
presence of another drug at its site of action. Though the interaction can be 
direct (e.g. two drugs share the same target receptor), pharmacodynamic 
interactions are often indirect, and result from interference with physiological 
mechanisms.40  
If two drugs that have the same pharmacological effect are given together, their 
effects can be additive. For example, even moderate amounts of alcohol can 
cause excessive drowsiness, if therapeutic doses of sedative drugs are taken 
simultaneously. Additive effects can occur both with the main effect of drugs, as 
well as with their adverse effects. For example, increased nephrotoxicity can 
occur with coadministration of otherwise unrelated nephrotoxic drugs.40 
In contrast to these additive pharmacodynamic effects, some drug combinations 
can oppose the activities of each other. For example, increased vitamin K intake 
can cancel the therapeutic effects of oral anticoagulants that inhibit vitamin K 
activation, and glucocorticoids can oppose the hypoglycaemic effect of oral 
antidiabetic drugs.40  
REVIEW OF THE LITERATURE: Drug metabolism and transport 
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2 Drug metabolism and transport 
Drugs are eliminated from the body by excretion and metabolism. Most drugs 
are lipid-soluble compounds, which require biotransformation into more 
hydrophilic form before they can be excreted from the body. A drug may be 
excreted by the kidneys into urine, by the liver cells into the bile and pass into 
the intestine, or end up in saliva (or milk). Drugs are most often metabolised in 
the liver by enzymes localised in the endoplasmic reticulum of hepatocytes, but 
significant drug metabolism occurs also in other tissues, e.g. gut wall during 
drug absorption.41,42 
The metabolism of drugs has been traditionally divided into “phase I” reactions 
(e.g. oxidation or hydrolysis) and “phase II” reactions (e.g. conjugation).41 
Phase I reactions usually produce functionalised and pharmacologically less 
active metabolites, whereas phase II reactions increase the water-solubility of 
the compounds and enhance their excretion.43 Drug transporters are involved in 
the cellular uptake of many drugs, and in the export of their metabolites.44  
Oxidation is a common pathway of xenobiotic metabolism, taking most often 
place in an intracellular organelle called the endoplasmic reticulum by the CYP 
system.  Reduction is a relatively uncommon pathway of drug metabolism, but 
hydrolysis of drugs by CYP enzymes and non-specific esterases is common.41,45,46  
Typically, the pharmacologically less active drug metabolite produced by 
oxidative (or other) reactions is conjugated to a water-soluble compound to 
produce an end product that can be more readily excreted. The 
biotransformation of a drug may produce several, even dozens of different 
metabolites.45    
The CYP system is often a crucial step in the overall elimination of drugs, and 
therefore a change in the activity (e.g. by inhibition) or amount (e.g. by 
induction) of CYP enzymes often results in alteration of the pharmacokinetics of 
drugs.6,47-50 Inhibition or induction of drug transporters may also alter the 
absorption, distribution or elimination of drugs.44  
2.1 CYP enzyme system 
2.1.1 Overview  
The cytochromes P450, CYP enzymes, are a superfamily of heme-containing 
enzymes, of which over 2700 individual members are currently known to exist in 
nature.51 They have been named after their characteristic absorption wavelength 
maximum (450 nm), seen when the reduced form of the enzyme is bound to 
carbon monoxide.52 The CYPs are able to metabolise a diverse group of 
substrates, both endogenous and xenobiotic, most often by catalysing oxidative 
reactions.  
The CYP system is arguably our most important xenobiotic metabolizing system, 
and approximately 80-90% of human drug metabolism is CYP-mediated.53-55 
Most of the CYP-catalysed reactions lead to detoxification of xenobiotics, 
involving the formation of more polar metabolites that are more readily 
excretable. However, the CYPs can also activate pro-drugs, or produce 




more toxic and reactive metabolites. To date, a total of 57 CYP enzymes have 
been identified in humans.46 The families CYP1, CYP2, and CYP3 are primarily 
associated with the metabolism of exogenous compounds, whereas the other 
CYPs have mainly endogenous roles.46 Degree of similarity in the amino acid 
sequence divides the CYPs into families (>40% identical, e.g. CYP1 family), 
subfamilies (>55% identical, e.g. CYP1A subfamily), and individual enzymes 
with unique sequence (e.g. CYP1A1 enzyme).56   
STRUCTURE AND TISSUE DISTRIBUTION The function of CYP enzymes is based on 
the catalytically active centre of the protein, formed around a heme.57 The 
overall sequence variability among CYP proteins is great, but they have a high 
conservation of their central structure and general topography.58 The most 
variable regions are associated with anchoring to membrane, and substrate 
binding and recognition. The substrate-recognition sites are flexible and move 
upon substrate binding to facilitate the catalytic process.59 CYPs are anchored on 
the outer face of the endoplasmic reticulum (ER) by hydrophobic anchors, with 
the active site exposed at the cytosolic face of the membrane.45   
The functions of CYPs are extremely diverse –from biosynthesis and catabolism 
of signalling molecules and steroid hormones to detoxification or activation of 
xenobiotics- and they can be found in all types of tissues, with developmentally 
regulated patterns of expression.60 The highest levels of CYPs are found in the 
liver, where they were first described.61 The small intestine has the second 
highest CYP content,62 and CYPs are present in lower quantities in many other 
tissues, such as the kidney, brain, and the respiratory tract.63 
In the liver, CYP3A4 is quantitatively the most important, with CYP2C8, CYP2C9, 
CYP2A6, CYP2E1 and CYP1A2 present in somewhat lower quantities; CYP2C19 
and CYP2D6 are of relatively minor quantitative importance, but their clinical 
importance is high.64 CYP3A4 is the major form of CYP expressed in enterocytes, 
and members of CYP2C subfamily are also significantly expressed.62 Microsomal 
protein content decreases along the small intestine from the duodenum to 
ileum.65   
CATALYTIC MECHANISM CYPs most often catalyse the insertion of one of the 
atoms of molecular oxygen into the substrate being biotransformed, while the 
second atom of oxygen is reduced to water. The most frequently catalysed 
reaction is hydroxylation, but the result of CYP-mediated catalysis can be e.g. a 
dealkylation, dehydrogenation, isomerisation or carbon-bond cleavage.60 The 
variety of CYP enzyme structures and the intrinsic reactivity of all their 
substrates explains the diversity of reactions catalysed by CYPs.46  
The details of the mechanism by which CYPs carry out all types of reactions are 
not fully understood. The best-documented aspect is the hydroxylation reaction 
that is common to most CYPs (Figure 1).  
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5. Release of the hydroxylated
metabolite
H2O
1. Binding of the substrate
2. Reduction of the heme iron and 
binding of molecular oxygen 
3. Release of water and formation
of an activated oxygen intermediate
4. Insertion of the activated oxygen
intermediate into the substrate
 
SUBSTRATE SELECTIVITY The CYPs have broad and often overlapping substrate 
specificities. It is possible that two or more CYPs contribute to the metabolism of 
a single compound, or that a single CYP can catalyse two or more metabolic 
reactions for the same substrate. Although more than one CYP can catalyse the 
biotransformation of a drug, they may do so with markedly different affinities. 
The selectivity of a substrate towards a particular CYP enzyme is based on 
differences in the number and spatial disposition of the relevant complementary 
structures on both substrate and enzyme molecules. The lipophilic character and 
molecular mass of the substrate also play a role in substrate recognition. Drug 
biotransformation in vivo is often determined by the CYP with the highest affinity 
for the drug. Thus, the rate of elimination of drugs can be largely determined by 
a single CYP enzyme or a combination of specific CYPs.6,51   
VARIATION IN CYP ACTIVITY The levels and activity of each CYP have been shown 
to vary from one individual to the next due to genetic, environmental, and host 
factors. Environmental and host factors include medications (e.g. 
anticonvulsants, rifampicin, antifungals, macrolides), foods (e.g. cruciferous 
vegetables, grapefruit), habits (alcohol consumption, smoking), age, hormonal 
status and disease status (infections, hyper- or hypothyroidism, hepatic 
failure).39,66   
Genetic variation observed in genes encoding CYP enzymes, are most commonly 
single nucleotide polymorphisms (SNP), but complete deletions and 




insertions of another gene copy also occur. Only a fraction of genetic variations 
have any functional consequence, but some of them lead to altered gene product 
function.67 In addition to interindividual differences, there are differences 
between ethnic groups in the frequencies of polymorphic variations of CYPs.68 A 
genetic polymorphism is defined as an inherited genetic difference that occurs 
with >1% population frequency. The gene encoding the enzyme protein (e.g. 
CYP1A1 enzyme) is presented in italics (e.g. CYP1A1), and specific alleles are 
presented by * and allele mark (e.g. CYP1A1*3 allele). The allele considered 
prevalent is called the “wild-type” allele.69 
2.1.2 Mechanisms of CYP induction  
CYP induction increases the capacity for metabolic detoxification. This is usually 
advantageous, protecting the individual against exposure to xenobiotics, but can 
also be harmful, e.g. if the induced enzyme catalyses the activation of a 
procarcinogen. Induction can alter drug efficacy or lead to drug–drug 
interactions. The predominant mechanism of human enzyme induction is 
increased gene transcription, leading to an increase in the amount of induced 
enzyme. Enhanced enzyme activity can also result from reduced degradation of 
the enzyme or stabilisation of the messenger RNA (mRNA). Although a given 
inducer can be quite selective for a single enzyme, there may be significant 
inductive effects on one or more additional CYPs and other enzymes.70,71   
Induction usually involves a transient increase in the rate of transcription that 
begins soon after exposure to the inducer, and returns to basal level when the 
inducer is eliminated from the body. Transcriptional activation of CYP gene 
expression occurs via binding of an inducing agent to an intracellular receptor, 
binding of the inducer-receptor complex to DNA response elements, followed by 
enhanced gene transcription. The overall inductive effect is a combination of 
several nuclear receptor-mediated processes. For example, the glucocorticoid 
receptor contributes indirectly to CYP induction by upregulating the nuclear 
receptors which themselves control the expression of CYPs.72  
The induction of the genes in the CYP1 family is under the control of the 
arylhydrocarbon receptor (Ahr), a transcription factor located in the cytosol and 
activated by binding of the appropriate inducing chemical (e.g. polycyclic 
hydrocarbons, PAHs).70,71 Three “orphan” nuclear receptors, constitutive 
androstane receptor (CAR), pregnane X receptor (PXR), and peroxisome 
proliferator activated receptor (PPAR), are key elements in the induction of the 
hepatic CYP2, CYP3, and CYPA4 families. Their endogenous ligands were 
previously unknown (hence the name “orphan”), but recently several ligand 
candidates have been identified (e.g. androstenol, corticosterone and arachidonic 
acid).71 Following activation by binding of appropriate ligand (e.g. phenobarbital 
for CAR, rifampicin for PXR, and clofibric acid for PPAR), they heterodimerise 
with retinoid X receptor (RXR) and bind to corresponding response element on 
the DNA, followed by subsequent increase in gene transcription. In addition to 
CYP enzymes, other drug-metabolising enzymes (e.g. UGTs)73 and P-
glycoprotein74 have been shown to be regulated by these nuclear receptors. CAR 
and PXR bind to the same DNA response elements, suggesting that their 
regulatory functions are overlapping.75-77  
2.1.3 Mechanisms of CYP inhibition  
A drug can inhibit the activity of the CYP that metabolises the drug itself, but 
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inhibition of other CYPs that play no role in the metabolism of the inhibitor itself 
also occur. The mechanism of CYP inhibition divides the inhibitors into reversible 
and irreversible (and quasi-irreversible) categories.39   
REVERSIBLE INHIBITION Reversible CYP inhibition is thought to be the most 
common mechanism causing pharmacokinetic drug–drug interactions. This type 
of inhibition is dose-dependent, and when the inhibitor is eliminated from the 
body, the normal metabolic function of the inhibited enzyme continues. 
Reversible inhibition can be further divided into competitive (prevalent), 
noncompetitive and uncompetitive types (Table I). The affinity with which the 
inhibitor binds to the enzyme is described by the inhibition constant (Ki), used to 
describe the inhibitory potency of a competitive inhibitor. The subtypes of 
reversible inhibition can be recognised according to the changes they produce in 
the observed kinetic constants of affected substrates in vitro, and Ki can be 
determined with graphical plotting methods or nonlinear regression models.71  
In competitive inhibition, the substrate and inhibitor compete with each other for 
the active site of the enzyme. The inhibitor can share structural similarity with 
the substrate(s) of the inhibited CYP, but this may not be apparent. Binding of 
the inhibitor to the active site of the enzyme prevents the binding and 
biotransformation of the substrate.71 In non-competitive inhibition, the inhibitor 
binds to the enzyme at a site distinct from the active site. The binding of the 
substrate to the enzyme active site is not affected, but the catalytic function of 
the enzyme-inhibitor-complex is not normal.71 In uncompetitive inhibition, the 
inhibitor binds only to the enzyme-substrate complex, that is, binding of the 
substrate to the enzyme must precede binding of the inhibitor.71  
IRREVERSIBLE INHIBITION Irreversible and quasi-irreversible inhibition require 
metabolical activation of the inhibitor by the affected CYP enzyme before forming 
an enzyme-inhibitor complex (Table I).78 Irreversible inhibitors are commonly 
called “catalysis-dependent”, “mechanism-based” or “suicide” inhibitors. 
Covalent binding of the activated inhibitor to the enzyme leads to irreversible 
inactivation of the enzyme.79 The formed covalent bonds between an irreversible 
inhibitor and enzyme cannot be broken to regenerate the enzymatic activity. In 
vivo, this sort of inhibition may start more slowly than reversible inhibition, but 
the final effect is usually more profound and is reversed only by synthesis of new 
CYPs.79     




Table I. The typical characteristics of different types of CYP inhibitors. 
Type of inhibition Onset of inhibition In vitro characteristics 
Reversible  Competitive Inhibitor binds to the enzyme 
active site 
Vmax remains constant, but Km 
decreases with increasing 
inhibitor concentration 
 Noncompetitive Inhibitor binds to a site distinct 
from the enzyme active site 
Km remains constant, but Vmax 
decreases with increasing 
inhibitor concentration 
 Uncompetitive Inhibitor binds to the enzyme-
substrate complex 
Vmax and Km decrease with 
increasing inhibitor 




 Metabolically activated inhibitor 
forms a quasi-irreversible complex 
with the enzyme 
Enzyme activity can be 
restored under experimental 
conditions 
Irreversible  Metabolically activated inhibitor 
binds covalently to the enzyme 
Enzyme activity cannot be 
restored; Kinact describes the 
rate of enzyme inactivation 
and KI is the inhibitor 
concentration where this rate 
is 50% of maximal 
 
2.1.4 CYP1 family  
The members of the CYP1 family (CYP1A1, CYP1A2, and CYP1B1) are involved in 
the metabolism of many aromatic compounds and in the generation of 
carcinogenic metabolites from PAHs.80-82  
CYP1A2 CYP1A2 is the most important isoform of the family, accounting for 
approximately 10% of the total liver CYP content (Table II).64,83 CYP1A2 is 
mainly expressed constitutively in the liver,64 and it has about 10-20 different 
substrate drugs (e.g. melatonin, caffeine, clozapine, and theophylline).6,81,84 
CYP1A2 inhibitors include furafylline and fluvoxamine.85,86 The plasma 
concentrations and effects of the CYP1A2 substrate tizanidine are drastically 
increased by fluvoxamine.87,88    
2.1.5 CYP2 family 
This is the largest and most diverse of the CYP families. Its members are 
primarily expressed in the liver, but CYP2C enzymes are found in significant 
quantities also in the intestine.89  
CYP2A6 CYP2A6 is predominantly a hepatic enzyme, representing about 10% of 
hepatic CYP proteins, and its substrates include nicotine and coumarine (Table 
II).6 CYP2A6 is inhibited by e.g. methoxalen, and it is induced by phenobarbital.6 
CYP2A6 is a highly polymorphic enzyme, with at least 16 distinct alleles 
identified, associated with absent or decreased enzymatic activity. CYP2A6 
polymorphism may have a role determining smoking behaviour as CYP2A6 is the 
major nicotine oxidase and defective CYP2A6 variants have decreased nicotine 
clearance.90-92    
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CYP2B6 Hepatic expression of CYP2B6 has been reported to vary from 0.2 to 7 % 
of total hepatic CYP, and it metabolises e.g. bupropion and propofol (Table 
II).93,94 CYP2B6 activity is inhibited by e.g. clopidogrel and ticlopidine,93 and it is 
inducible by phenobarbital and rifampicin. In addition to the wild type allele, 
seven variant forms of CYP2B6 have been identified, but their functional 
significance is not completely understood.50,67  
CYP2C SUBFAMILY This family comprises CYP2C8, CYP2C9, CYP2C18, and 
CYP2C19, which collectively are responsible for the metabolism of about 20% of 
clinically prescribed drugs.81 CYP2C enzymes are expressed in the liver and 
intestine, where they are the most expressed CYP subfamily after CYP3A.65,89 
CYP2C8 CYP2C8 constitutes about 12% of total microsomal CYP content in the 
liver (Table II), and the enzyme is characterised by a relatively large active 
site.83 Though CYP2C8 is found also in the intestine, intestinal CYP2C8 content is 
small and unlikely to play an important role in drug metabolism.89 
CYP2C8 metabolises arachidonic acid and retinoid acid,95,96 and it also plays an 
important role in the metabolism of drugs such as amiodarone,97 cerivastatin,98  
paclitaxel,99 and repaglinide.7 Extrahepatically, CYP2C8 appears to be important 
in the activation of  arachidonic acid in the kidney.100 CYP2C8 inhibitors include 
trimethoprim, montelukast, quercetin, and gemfibrozil.101,102 CYP2C8 expression 
is induced by e.g. rifampicin, phenobarbital, and dexamethasone.6   
In addition to the wild-type allele, at least four variant CYP2C8 alleles are 
known. CYP2C8*2 is very rare, CYP2C8*3 has a frequency of 13% and 
CYP2C8*4 a frequency of 7.5% in Europeans; in Africans the frequencies are 
different. Variant CYP2C8 forms are associated with a decreased activity 
compared to the wild type enzyme when using paclitaxel as substrate.103 
CYP2C9 CYP2C9 is expressed both in the liver and in the intestine, and the 
CYP2C9 content of the liver is approximately 10-fold higher than in the intestine 
(Table II). CYP2C9 is the predominant CYP2C isoform both in the intestine and 
liver.89 Substrates of CYP2C9 include S-warfarin, S-ibuprofen, losartan, and 
phenytoin.104 CYP2C9 is inhibited by e.g. sulfaphenazole, voriconazole, and 
fluconazole,104 and it is induced by rifampicin, dexamethasone, and 
phenobarbital.6   
Several variant CYP2C9 alleles have been described, characterised by impaired 
enzymatic activity. The variants forms alter the pharmacokinetics of CYP2C9 
substrate drugs, and about 1% of Caucasians have a low CYP2C9 activity.50,67 
For example, a relationship between warfarin dose requirement and CYP2C9 
genotype has been found in several studies.105-107 
CYP2C19 CYP2C19 is functionally expressed in the liver and intestine,89 and its 
substrates include diazepam, protein pump inhibitors (e.g. omeprazole), and 
citalopram (Table II).53 CYP2C19 is inhibited by fluconazole and fluvoxamine, 
and induced by phenobarbital and rifampicin.6 Some variant CYP2C19 alleles 
(CYP2C19*2 and *3) do not produce functional protein, leading to impaired 
metabolism. For example, the absence of functional CYP2C19 has been 
associated to better response to peptic ulcer treatment with omeprazole and 
impaired diazepam elimination.50,67 Recently identified CYP2C19*17 allele has 
been reported to cause ultrarapid metabolism by enhancing CYP2C19 




expression.108    
CYP2D6 CYP2D6 is expressed in the gut wall and the liver, and it represents  
about 2% of total hepatic CYP content (Table II).51 CYP2D6 substrates include 
amitriptyline, codeine, and metoprolol.53 CYP2D6 is inhibited by e.g. quinidine, 
and it has not been shown to be inducible by drugs. There is considerable 
genetic variation in CYP2D6 activity, and people can be divided into poor, 
extensive, and ultrarapid metabolisers based on the CYP2D6 genotype.50,67  
CYP2E1 CYP2E1 is mainly found in the liver, and it accounts for about 7-9% of 
hepatic CYP content (Table II). CYP2E1 substrates include acetone, ethanol, 
benzene, halothane, isoflurane, and paracetamol,53 and CYP2E1 is inhibited by 
e.g.  disulfiram. Increased metabolic function of CYP2E1 in response to inducing 
agents (e.g. ethanol, acetone) is mediated through multiple induction 
mechanisms. CYP2E1 is the major enzyme converting paracetamol to its reactive 
intermediate, and CYP2E1 induction (by e.g. excess ethanol consumption) 
predisposes to liver damage from therapeutic paracetamol doses.50,67   
2.1.6 CYP3 family  
The CYP3A subfamily accounts for approximately 30-40% of the total CYP 
content in the human liver,53 and CYP3A4 is involved in the metabolism of about 
50% of drugs.81 CYP3A genes are highly inducible, by e.g. rifampicin, 
barbiturates and dexamethasone.109   
CYP3A4 CYP3A4 is the most abundant CYP isoform in the liver and intestine 
(Table II).64 Observed CYP3A4 activity varies considerably between individuals, 
at least partly due to substrate overlap with variably expressed CYP3A5 and 
CYP3A7 enzymes.81  
CYP3A4 substrates include, for example, midazolam, simvastatin, cyclosporine, 
and triazolam.53 CYP3A4 inhibitors include e.g. ketoconazole, itraconazole, 
erythromycin, and grapefruit juice.110 CYP3A4 inducers include rifampicin, 
phenytoin, phenobarbital, and carbamazepine.6,111 Induction of CYP3A4 has been 
shown to occur both in the liver and in the intestine.112  
A substantial number of variant CYP3A4 alleles have been described, but their 
population frequencies are very low, and they are unlikely to explain the 
variability of CYP3A4 activities. The observed activity differences may be 
explained by variation in the functions of transcriptional regulators of CYP3A4 
(e.g. PXR).50,67   
CYP3A5 CYP3A5 is found mainly in the liver but also in extrahepatic tissues such 
as the intestine.113 The substrate specificity of CYP3A5 is similar (but not 
identical) to that of CYP3A4, but the catalytic efficiency of CYP3A5 is usually 
smaller than that of CYP3A4. Erythromycin and midazolam are metabolised 
efficiently by CYP3A4 and CYP3A5, whereas CYP3A4 is a more efficient 
metaboliser of quinidine, testosterone, and irinotecan than CYP3A5.6 CYP3A5 
shows a polymorphic expression pattern, and significant amounts of the enzyme 
(product of CYP3A5*1) are expressed in only 10-20% of caucasians. CYP3A5*3, 
producing a nonfunctional protein, is very common in all ethnic groups.50,67     
CYP3A7 CYP3A7 is normally expressed only in the in the fetal liver, but some 
adults continue to express this enzyme. CYP3A7 expression may be a 
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contributory factor to the high overall variability of CYP3A activity in adults.50,67 
2.1.7 Other drug-metabolising enzymes  
In addition to CYP enzymes, there are also many other enzymes localised in the 
endoplasmic reticulum or cytosol that contribute to drug metabolism, and many 
of these enzymes catalyse the same reactions as CYPs. Flavin mono-oxygenases 
catalyse the oxidation of e.g. nortriptyline, verapamil, and cimetidine.114 
Monoamine oxidases (MAOs) metabolise the brain transmitters dopamine and 
serotonin, and MAO inhibitors are used as antidepressants (e.g. moclobemide) or 
to treat Parkinson’s disease (e.g. selegiline).114-116 Alcohol and aldehyde 
dehydrogenases catalyse the oxidation of alcohols and aldehydes to carboxylic 
acid metabolites.114 Xanthine oxidase metabolises purine compounds to uric acid, 
and its inhibitor allopurinol is used in the treatment of gout.114 Members of the 
paraoxonase enzyme family hydrolyse several insecticides, and appear to be 
protective against the development of atherosclerosis by hydrolysing derivatives 
of oxidised cholesterol.114,117     
  





















































































Amiodarone    
Cyclosporine
Felodipine      
Midazolam
CYP3A4 #~20-29%       
InducersInhibitorsSubstratesRelative hepatic abundance of 
CYP isoforms*
* Individual CYP contents vary considerably, data from Rodrigues 1999 (n=12) and Shimada et al. 1994 (n=60).
# Polymorphically expressed CYP3A5 shares several substrates with CYP3A4.
† These enzymes exhibit significant polymorphism.
Table adapted from Pelkonen et al. 1998 and Ingelman-Sundberg 2003.
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2.2 Conjugating enzymes 
The conjugating enzymes use the functional groups originally present in their 
substrates, or introduced by drug-metabolising enzymes, to attach them to 
additional molecules. The addition of a conjugate, such as glucuronic acid, 
usually results in pharmacological inactivation of the drug or metabolite, but in 
some cases this can be an activating step. The product conjugates are more 
water-soluble and more readily eliminated from the body.41   
UDP-GLUCURONOSYLTRANFERASES (UGT) The UGTs are a superfamily of 
membrane-bound enzymes that catalyse the conjugation of glucuronic acid to 
their substrates. The tissue distribution and intracellular location of UGTs is 
similar to that of CYPs, but their active site is inside the endoplasmic reticulum. 
UGTs have broad and overlapping substrates specificities and can conjugate 
different types of functional groups. Their substrates include endogenous 
compounds such as steroids, bilirubin and retinoid acid in addition to 
xenobiotics.41,118   
SULFOTRANSFERASES (SULT) Sulfonation modulates the biological activity of 
xenobiotics, hormones and neurotransmitters, but also the receptor activity of 
e.g. estrogens and androgens. SULTs are enzymes found primarily in the cytosol, 
and they catalyse the transfer of a sulfonate group to their substrates. SULTs 
form a large superfamily of genes; SULT1 and SULT2 families are responsible for 
the sulfonation of the greatest number of compounds.41,119     
GLUTATHIONE TRANSFERASES (GST) The GSTs are mainly cytosolic enzymes that 
catalyse the conjugation of glutathione group to suitable substrates, but act also 
to remove reactive oxygen species. The conjugates produced by GSTs are water-
soluble, and require active transport out of the cell by e.g. multispecific organic 
anion transporter (MOAT) or P-glycoprotein.41,120   
ARYLAMINE N-ACETYLTRANSFERASES (NAT) The function of NATs is to conjugate 
an acetyl group to appropriate substrates. Humans express two distinct 
isoenzymes, NAT1 and NAT2. Clinically relevant NAT substrates include the 
antiarrhythmic procainamide, several antibacterial sulphonamides, caffeine, and 
many industrial and environmental carcinogens.41,121    
METHYLTRANSFERASES Methyltransferases catalyse the methylation of many 
drugs, neurotransmitters and hormones, and even macromolecules such as 
proteins and DNA.41 Catechol O-methyltransferase (COMT) is found in a cytosolic  
and a membrane-bound form, and its substrates include neurotransmitters 
dopamine, noradrenalin and adrenaline and drugs L-dopa and methyldopa. 
Thiopurine methyltransferase (TPMT) is a cytosolic enzyme, which catalyses the 
S-methylation of e.g. 6-mercaptopurine. Methylation mediated by the cytosolic 
histamine N-methyltransferase (HNMT) has been shown to be a major pathway 
of histamine metabolism.41,122  
2.3 Drug transporters 
The physicochemical properties of a drug (pKa, size, lipophilicity) affect drug 
movement through biological barriers, but the action of drug transporters also 
has a significant impact on drug disposition and elimination. The substrate 





selectivity, direction of action (moving substrates into or out of the cell), 
intracellular location (in the basolateral or apical cell membrane), and tissue 
distribution (in e.g. the intestine, kidney, liver, or brain) of transporters 
determine how they affect drug movement between biological compartments. In 
addition to drugs, these transporters also transport endogenous substances 
(sugars, lipids, amino acids, bile acids and hormones).44,123-125    
In the small intestine, enterocytes contain several transporters that are 
important in the absorption of dietary constituents and drugs, but also 
transporters that limit drug absorption. P-glycoprotein is a particularly important 
efflux transporter that limits the extent of drug absorption by pumping its 
substrate drugs back into the gut lumen.43   
In the liver, uptake transporters (e.g. OATPs) expressed on the basolateral 
membrane of hepatocytes extract their substrate drugs from the portal blood. 
Once inside, drugs often undergo metabolic transformation and/or conjugation, 
or they may be excreted unchanged into bile. The final step of transport of drugs 
from portal blood into bile can be mediated by efflux transporters (e.g. P-
glycoprotein) localised on the canalicular membrane of the hepatocyte.44,123-125   
In the kidney, combined function of uptake and efflux transporters localised to 
the basolateral and apical membranes of tubular cells can affect the direction 
and efficacy of drug passage. Other factors, such as urine pH and glomerular 
permeability of the drug are often more important in determining the amount of 
drug excreted into urine.43  
In the blood-brain barrier, formed mainly by capillary endothelial cells, drug 
transporters are an important component limiting the access of drugs into brain 
tissue. While uptake transporters act to import glucose and amino acids to brain, 
efflux transporters such as P-glycoprotein prevent entry of their substrate 
drugs.43  
The placenta is the structural barrier between the mother and the developing 
fetus, and there are various transporters both in the maternal-facing and fetal-
facing placenta membranes. For example, P-glycoprotein has a major functional 
role in the maternal blood-placenta barrier,126 while OAT4 is localised in the 
fetal-facing surface, and thought to have a role in the placental uptake of fetal-
derived compounds.44,123-125  
Compared to the CYP enzymes, relatively little is known about the functions of 
drug transporters. Differentiation of the role of a particular transporter in drug 
pharmacokinetics is difficult, because the substrate specificities of different 
(efflux and influx) transporters, expressed variably in organs relevant to 
pharmacokinetics (e.g. intestine, liver, and kidney) may overlap considerably. A 
complicating factor is that in studies conducted in humans, drug concentrations 
are usually measured only from blood (and urine), and knowledge of tissue 
concentrations is lacking. Furthermore, the study of drug transporters in vitro is 
more complicated than that of drug-metabolising enzymes, because the action of 
transporters is directional and requires a cell membrane.44,123-125  
The induction and inhibition of drug transporters follow the same principles 
described for drug-metabolising enzymes. Induction of several drug transporters 
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is mediated by the same nuclear receptors that regulate CYP gene expression. 
PXR activation has been shown to induce P-glycoprotein, MRP2 (also induced by 
CAR activation), and OATP1B1. Inhibition of drug transporters important to drug 
elimination (e.g. hepatic uptake or biliary/renal excretion) or limiting absorption 
(in the intestine) can lead to drug-drug interactions. For example, inhibition of P-
glycoprotein by clarithromycin has been shown to increase the AUC of digoxin (a 
high-affinity P-glycoprotein substrate).44,127,128  
2.3.1 Uptake transporters  
Uptake (influx) transporters facilitate the entry of drugs into cells. Uptake 
transporters include the organic anion transporting polypeptide (OATP), the 
organic anion transporter (OAT), organic cation transporter (OCT), and peptide 
transporter (PEPT) families (Table III).44,123,129  
Three organic anion transporting polypeptides (OATPs) have been identified in 
the human liver, located at the sinusoidal membrane of hepatocytes and extract 
compounds from portal venous blood. Efflux of intracellular glutathione has been 
suggested to be a driving force for OATP-mediated transport.44,124,129  
Organic anion transporters (OATs) are multispecific transporters expressed in a 
variety of tissues, such as kidney, liver, brain and placenta. The transport 
mechanism of OAT1 and OAT3 utilises the Na+ gradient of the plasma 
membrane, but the mechanism of OAT2- or OAT4-mediated transport is not well 
characterised. In the kidney, OAT1 and OAT3 are localised on the basolateral 
membrane of the proximal tubule cells and take up drugs from blood.44,124,129  
The members of the organic cation transporter (OCT) family act to transport 
various small organic cations, but interact also with larger cations.44,124,129 
Peptide transporters (PEPTs) are located in the membrane of intestinal and renal 
epithelial cells, where they mediate the uptake of peptides produced by protein 
digestion, as well as structurally related compounds (e.g. ß-lactam 
antibiotics).44,130   
2.3.2 Efflux transporters  
Efflux transporters act to limit the entry of drugs or enhance their removal from 
the cell, and are present in many tissues (e.g. intestine, blood-brain barrier, 
hepatocytes, and placenta). P-glycoprotein (MDR1), multidrug resistance-
associated protein family (MRP), and the breast cancer resistance protein (BCRP) 
are the efflux proteins most relevant to drug disposition, but their substrates 
also include sugars, amino acids, cholesterol and proteins.123,128,131   
P-GLYCOPROTEIN (MDR1) P-glycoprotein is found at the hepatocyte canalicular 
membrane, on the apical side of gastrointestinal epithelial cells, on the surface of 
endothelial cells of brain capillaries, in the placenta, and in the testis. P-
glycoprotein reduces the absorption in the intestine and enhances the excretion 
of drugs into the bile or into urine. P-glycoprotein plays also an important role in 
protecting the brain and testis by limiting their exposure to drugs.127,131-133   





Table III. The tissue distribution of selected uptake transporters, and examples of their 
substrates. 




(OATPs)    
OATP1B1, OATP1B3, 
and OATP2B1 in the 
liver; OATP2B1 also in 
the lung, brain, kidneys
OATP1B1: methotrexate, rifampicin, atorvastatin, 




Kidney, liver, brain, 
and placenta 
OAT1: NSAIDs, ß-lactam antibiotics, diuretics and 
ACE-inhibitors; OAT2: NSAIDs, antibiotics; OAT3: 
steroid conjugates, NSAIDs, and diuretics; OAT4: 
steroid conjugates, antibiotics. 
Organic cation 
transporters (OCTs) 
OCT1: liver, intestine; 
OCT2: kidney 
OCT1: dopamine, cimetidine, metformin 
Peptide transporters 
(PEPTs) 
PEPT1: small intestine, 
kidney, liver; PEPT2: 
kidney, brain, lung, 
mammary gland 
PEPT1, PEPT2: Dipeptides, tripeptides, ß-lactam 
antibiotics, ACE inhibitors 
References in text. 
The substrates, inhibitors, and inducers of P-glycoprotein are structurally 
diverse, but overlap with those of CYP3A4. It has been suggested that P-
glycoprotein and CYP3A4 function together to limit oral drug bioavailability, but 
evidence in humans is limited.134 P-glycoprotein substrates include digoxin, 
doxorubicin and vinblastine, and its activity is inhibited by e.g. quinidine, 
verapamil or cyclosporine. Inducers of P-glycoprotein include e.g. rifampicin and 
St. Johns wort.127,131-133  
MDR-RELATED PROTEINS (MRP) MRPs are organic anion efflux pumps that 
transport glutathione, glucuronide or sulphate conjugates of drugs, and also 
unconjugated drugs (e.g. macrolide antibiotics). They are found in several 
tissues, e.g. in the liver, gut, kidney, brain and placenta. Due to their cellular 
locations, MRP1 and MRP3 secrete drugs into, while MRP2 moves drugs out of 
the body.128,131,135   
MRP1 is located in various tissues, but has low expression in the liver. MRP2 is 
located in the canalicular membrane of the hepatocyte, on the apical membrane 
of intestinal enterocytes, and in the proximal tubule in kidney. MRP2 substrates 
include pravastatin, ceftriaxone, and ciprofloxacin, and its activity is inhibited by 
e.g. probenicide. MRP3 is expressed in the basolateral membrane of the 
hepatocyte and basolateral membrane in kidney tubules.128,131,135  
BREAST CANCER RESISTANCE PROTEIN (BCRP) BCRP is present in the placenta, 
intestine, liver, and capillaries, and its substrates include mitoxantrone, 
anthracyclines, and topotecan. The role of BCRP in the hepatic distribution of 
drugs remains to be determined, but it appears to be have an active role limiting 
drug entry into CNS.128,131   
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3 In vitro studies on drug metabolism   
In vitro drug metabolism studies are used to estimate risks of drug-drug 
interactions, and also to predict human pharmacokinetics in the development of 
drugs. The properties of drugs characterised using in vitro methods can be used 
to guide the planning of studies conducted in humans. For example, when the 
principal enzymes responsible for the biotransformation of a drug have been 
identified in vitro, estimates can be made of its susceptibility to drug-drug 
interactions caused by inhibition of its metabolism. Conversely, the inhibitory 
properties of a drug can be used to estimate its effect on the metabolism of 
other drugs.83,136,137   
Compared to clinical studies, the in vitro drug metabolism studies are faster and 
cheaper to conduct, and do not require human exposure. However, they have 
numerous intrinsic problems (e.g. non-specific binding of drugs to microsomes, 
the need for organic solvents) and cannot incorporate many determinants of 
human drug disposition (e.g. plasma protein binding, hepatic blood flow). 
Though in vitro data can be used to predict the likehood of clinical drug 
interactions, studies conducted in humans are needed to draw reliable 
conclusions. Human liver microsomes (HLM) are the most widely used source of 
human enzymes used in in vitro drug metabolism studies, while other 
alternatives include cDNA-expressed CYP enzymes (rhCYPs), isolated/cultured 
hepatocytes, liver slices, and purified CYP enzymes.138-140   
3.1 In vitro systems  
HUMAN LIVER MICROSOMES (HLM) HLM are prepared from homogenised liver 
tissue by differential centrifugation. HLM contain all the CYP enzymes expressed 
in the human liver in the same proportions that they occur in vivo.  By pooling 
several liver tissue samples, the individual variation in enzyme content can be 
minimised, but each HLM batch is still slightly different. Pooled HLM contain the 
“average” levels of all CYPs expressed in the livers taken into the pool. The ratio 
of NADPH-reductase to CYP, the amount of cytochrome b5, and the type of lipids 
are same as those in the intact liver. The same sample of pooled HLM can be 
used to study all CYPs of interest, and they contain the enzymes required to 
study metabolism-dependent inhibition. HLM contain, however, large amounts of 
lipids and proteins that can significantly bind the studied drugs, though this 
problem is common to all in vitro systems. In HLM, enzyme-selective inhibitors 
must be used when assessing the role of a particular CYP in the metabolism of a 
substrate.83,141-143   
cDNA-EXPRESSED HUMAN CYP ENZYMES (rhCYP) rhCYPs can be produced e.g. in 
insect cells and human lymphoblast-derived cells, and in this system all the 
activity comes from the particular expressed CYP enzyme. In contrast to HLM, 
the metabolism of the substrate by a specific CYP can be directly evaluated. The 
variable expression of cytochromes b5 and/or NADPH-reductase can affect the 
Vmax determined for a given enzyme, although the Km values towards marker 
substrates are generally comparable between rhCYPs and HLM. When a 
substrate is metabolised by several CYPs, the Km observed in HLM differs from 
that obtained using a single rhCYP. rhCYPs are useful when e.g. trying to 
differentiate relative importance of different CYPs that metabolise the same 
compound. Generally, rhCYPs are not suitable for metabolism-dependent 





inhibition experiments, if the target of the inhibitory metabolite is other than the 
enzyme responsible for its formation. Studies with rhCYPs give information only 
about one CYP at a time, and the properties of e.g. different polymorphic CYPs 
can be compared.83,137,141-143   
PURIFIED RECONSTITUTED CYP ENZYMES A functional CYP can be reconstituted 
from homogenous purified enzymes by mixing CYP, NADPH-reductase and 
phospholipids. However, it is often difficult to reconstitute them reproducibly, 
and the amount of NADPH-reductase is often higher than that present in HLM. 
Furthermore, not all CYPs are available in purified form.83,137,141-143   
HEPATOCYTES AND LIVER SLICES Hepatocytes offer some advantages over HLM 
system and are useful for the study of induction or integrated metabolism, but 
have several additional problems. For example, the interaction between two 
specific drugs might be studied successfully in hepatocytes if the mechanism of 
inhibition is complex. Michaelis-Menten enzyme kinetic equations do not usually 
apply to hepatocytes, and it is extremely difficult to interpret the obtained data 
mechanistically. The inhibitor may compete for cellular uptake in addition to 
metabolic biotransformation, and conjugation of the substrate may complicate 
the determination of metabolite formation. Isolated hepatocytes are hard to 
obtain, and repetition of experiments is difficult as CYP expression of 
hepatocytes is markedly decreased in culture. Liver slices, in addition to having 
the problems mentioned above, have a barrier to the diffusion of drugs to the 
cells inside the slice.83,137,141-143   
3.2 Enzyme kinetics 
Most CYP-mediated reactions follow simple Michaelis-Menten (MM) kinetics. The 
MM model assumes that the active site of the enzyme contains one binding site, 
where the catalytic process occurs, and that the velocity of the reaction can be 
characterised as a hyperbolic saturating profile. The classic enzyme kinetic 
concept is:141   
E + S  ES  E + P  
where E=enzyme, S=substrate, ES=enzyme-substrate complex, and P=product.   
The reaction rate (v) depends on the concentration of both unbound enzyme and 
substrate. When the enzymes are saturated by substrates, the enzyme catalytic 
rate reaches a maximum (Vmax). Km is the substrate concentration where the 











Some kinetic observations in vitro are less straightforward, with some CYPs (e.g. 
CYP3A4) exhibiting unusual properties such as substrate activation, substrate 
inhibition, partial inhibition and differential kinetics. Multiple binding site–models 
have been proposed to describe these “atypical” enzyme kinetics. For example, 
the two-site model hypothesises that two (similar or different) substrate 
molecules can bind simultaneously to the enzyme active site. Due to steric, 
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allosteric or electronic effects they may interact in a way that leads to altered 
kinetic properties.144  
3.3 Identification of CYP enzymes responsible for drug metabolism 
“Reaction phenotyping” or “enzyme mapping” is the process of identifying CYPs 
responsible for the metabolism of a given compound. This helps to predict the 
effect of polymorphisms, environmental factors, and other drugs on the overall 
metabolism and elimination of the drug of interest.83,136,137,142     
There are several available approaches for reaction phenotyping, and a 
combination of methods is usually needed to identify which human CYPs are 
responsible for the metabolism of a given drug. The rate of metabolism of the 
drug can be measured in several HLM samples, and reaction rates correlated 
with the variation in the CYP levels or activities of the individual samples. The 
importance of individual CYPs in the metabolism of the drug can be studied using 
pooled HLM and known chemical inhibitors or inhibitory antibodies of selected 
CYPs. Marked inhibition of the total metabolism of a drug in the presence of a 
selective CYP isoform inhibitor implies that this CYP significantly metabolises the 
drug. Using rhCYPs one can determine whether a particular CYP is able to 
metabolise the drug, but the importance of this enzyme in the overall 
metabolism of the drug is difficult to reliably predict from rhCYP data alone due 
to scaling problems.83,136,137,142  
The relative importance of CYPs can vary at different substrate concentrations, 
as the substrate selectivity of CYPs diminishes with increasing substrate 
concentration. For example, if in vitro metabolism studies are performed at 
substrate concentrations greatly exceeding the in vivo concentrations, the 
enzymes that appear to be most important in the biotransformation of a drug 
may not be the same as those responsible for its biotransformation in 
vivo.83,136,137,142   
3.4 Characterising the inhibitory properties of drugs 
CYP inhibition studies enable the prediction of the effect of the drug of interest 
on the metabolism and elimination of other drugs. The inhibitory efficiency of a 
drug can be described by determining IC50 to a reaction or Ki value for a specific 
CYP. IC50 value, the inhibitor concentration that causes 50% inhibition of 
measured activity, is dependent of the experimental conditions (type and 
concentration of the substrate, protein concentration, incubation time etc.). The 
Ki value is more laborious to determine, but is more reliable. The Ki is a measure 
of the affinity of the inhibitor for the enzyme and can be reproduced from one 
laboratory to another regardless of the precise experimental 
conditions.136,137,140,142,145,146    
A designed pool of HLM is more suitable than random HLM samples to overcome 
individual variability in the CYP content, and experiments are ideally performed 
under initial-rate reaction conditions, where the metabolic consumption of the 
substrate does not exceed 20%. For each CYP model reaction studied, variable 
amounts of microsomes and incubation times are required to allow sufficient and 
reliable generation of metabolites. Both excessive binding and metabolism of the 





inhibitor may cause limitations to the amount of drug available to inhibit the 
CYP.136,137,140,142   
When determining the IC50 values for direct CYP inhibition, various (e.g. four to 
six) concentrations of the inhibitor are incubated with HLM in the presence of the 
same concentration of the marker substrate. The data obtained from these 
samples is used to calculate the IC50 value by nonlinear regression. More data is 
needed for determining the Ki value; this experiment can be thought of as four 
or five separate sets of IC50 assays with a different substrate concentration in 
each. The type of inhibition can be determined visually from the plotted data, 
and nonlinear regression can be used to determine the Ki value.137,140,143,145,146    
The possibility of metabolism-dependent inhibition (e.g. mechanism-based) must 
also be studied. For detection of metabolism-dependent inhibition, the inhibitor 
is preincubated with NADPH in HLM to allow for the generation of possible 
inhibitory metabolites. After the preincubation, the marker substrate is added, 
and the incubation continued to measure residual CYP activity. If the 
preincubation substantially increases the observed inhibition, the inhibitor is at 
least partially metabolism-dependent.137,140,143   
There are several problems when determining the inhibitory characteristics of 
drugs. Many drugs have poor aqueous solubility at physiological pH, limiting the 
highest concentration of the drug that can be achieved in vitro. Dissolving the 
drug in an organic solvent (such as methanol, acetonitrile, etc.) or weakly acidic 
solutions, delivers the drug to the incubation mixture. Organic solvents, 
however, tend to be also substrates for CYPs, and can potently and selectively 
inhibit their activities. No organic solvent is optimal for all CYPs and the final 
concentration should be kept as low as possible.138,140,145,146      
The CYP marker reaction studies should be studied under initial-rate conditions, 
i.e. where the formation of the metabolite is directly proportional to incubation 
time and protein concentration, and the percentage of substrate metabolism 
does not exceed 20% (preferably 10%). The effect of substrate overmetabolism 
is seen as an apparent decrease in the inhibitory capacity of the drug (and 
higher Ki).141   
3.5 In vitro-in vivo extrapolation  
The use of in vitro inhibition results to make in vivo interaction predictions is 
difficult due to the intrinsic differences between the simplified non-physiological 
in vitro models and the dynamic (and only partially understood) drug-eliminating 
systems of human bodies. The ratio of the plasma concentration of an inhibitor 
[I] in vivo (e.g. Cmax) to its inhibitory constant (Ki) can be used to predict the 
probability with which the inhibitor would cause a clinically significant interaction 
with a substrate for the affected isoenzyme. Consideration should not include 
only the estimated AUC ratio alone, but include also the margin of safety of 
possible victim drugs, and their pharmacokinetic profiles. For substrates 
metabolised via multiple pathways, the inhibition of a minor metabolic pathway 
(e.g. <30% of total clearance) is not likely to cause a pharmacokinetically 
significant effect.145 136,137,140   
The extent of interaction can be predicted according to the following equation:16     
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AUC ratio 1 = R1 = 1+ [I]/Ki    
In this equation it is assumed that the substrate is metabolised 100% by the 
inhibited CYP. The fraction of substrate metabolised via inhibited pathway (fm) 
can be incorporated by use of the following equation:16  
AUC ratio 2 = R2 = 1 / [(fm/R1) + (1-fm)]   
Intrinsic clearance (CLint) for rhCYP or HLM can be calculated from CLint=Km/Vmax. 
To directly compare rhCYPs reaction data with that obtained using HLM, scaling 
factors are needed because the enzyme content of the systems is different. One 
approach is to use the relative activity factor (RAF), describing the amount of 






max =  , where Vmax refers to metabolism of a probe substrate 
by an individual CYP. However, RAFs are specific for the enzyme and the 
substrate used, and the use of intersystem extrapolating factors (ISEF), based 
on data from several reactions and CYP abundances in HLM, has been suggested. 
ISEF scaling factors are specific for one CYP enzyme, and have been determined 
using differences in either Vmax or CLint of various reactions.147  
From the CLint determined in HLM, the human liver CLint can be estimated using 
scaling factors for the microsome content of human liver (48.8 mg microsomal 
protein/g liver),148 and the liver weight for a given body weight (25.7 g liver/kg 
body weight).149 From this, the hepatic blood clearance (CLh) can be estimated 
from human liver CLint using the well-stirred model:150  
CLh = Q·fu·CLint/(Q+fu·CLint) 
where  Q = hepatic blood flow (20 mL/min/kg)151  
 fu = the unbound fraction of drug in blood 
 
SELECTION OF [I] AND Ki The selection of the most appropriate value of inhibitor 
concentration used in in vitro-in vivo interaction predictions can be difficult. The 
most conservative choice is the peak plasma concentration, but presumably the 
unbound concentration in plasma is closer to the intracellular drug concentration. 
Estimates have been made to determine the most accurate way to calculate 
[I]/Ki ratio, but there is no clearly established method to directly predict clinical 
drug interactions on the basis of in vitro CYP inhibition data.136,137  
Though more reliable than the IC50 value, the experimental Ki may also vary 
depending upon the in vitro approach used. Microsomal protein concentration, 
and nonspecific binding of substrate to microsomes are determinants of the 
apparent inhibitory potency of CYP inhibitors.139 Relative activity factors and 
intersystem extrapolation factors have been recommended for application of Ki 
values derived from rhCYP systems.147  Failure to account for atypical kinetics in 
in vitro experiments that are not described by Michaelis-Menten equation can 
also give rise to errant values of Ki.144    





4 Repaglinide in the treatment of type 2 diabetes 
4.1 Treatment principles of type 2 diabetes mellitus 
Diabetes mellitus (DM) is a disorder of carbohydrate metabolism characterised 
by elevated blood glucose, where the action of insulin is reduced because of 
impaired secretion or decreased insulin sensitivity. Complications such as retino- 
nephro-, and neuropathy, cardiovascular disease and foot ulceration follow the 
progress of the disease. Type 1 DM usually develops before adulthood, and the 
patients require exogenous insulin therapy to live. Type 2 DM typically develops 
later in life and in this condition normal (or even excessive) insulin secretion is 
insufficient to compensate for the developing insulin resistance.152-154    
Type 2 DM is a progressive disease where the symptomatic phase is preceded by 
a preliminary phase of impaired glucose tolerance. Type 2 DM is associated with 
obesity, and treatment of the obese patient should be started with changes in 
diet, increased exercise and weight reduction. Management of the disease 
usually requires stepwise adjustment of drug therapy in addition to lifestyle 
changes. If treatment with one oral antidiabetic fails, then a different type of 
drug, or a combination of different agents with complementary modes of action 
may improve the situation, but patients may ultimately need insulin injections as 
the disease advances. Tight glycemic control in type 2 DM is important in the 
prevention complications, but the management of dyslipidaemia (with e.g. a 
statin or fibrate) is also crucial for hyperlipidaemic diabetic patients.152-154   
The two major classes of oral antidiabetic drugs are sulphonylureas and 
biguanides. Sulphonylureas act mainly by increasing endogenous insulin 
secretion, while biguanides act by decreasing hepatic glucose production and 
increasing peripheral consumption of glucose.37,152,153,155 They both require at 
least some endogenous insulin production for their function, and are often used 
together. More recently developed classes of oral antidiabetics include the 
glitazones (thiazolidinediones), which act by increasing insulin sensitivity by 
altering glucose metabolism,152,156 and meglitinide analogs (e.g. repaglinide). 
Meglitinides have a mechanism of action similar to that of sulphonylureas, but 
they are more rapidly absorbed and eliminated. They are taken with meals, and 
due to their shorter duration of action, the risk of hypoglycaemia is smaller 
compared to sulphonylureas.152,157 Other alternatives include alpha-glucosidase 
inhibitors and guar gum, which delay and decrease glucose absorption from the 
gut (Figure 2). 152,153    
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Figure 2. The mechanism of action of different oral antidiabetic drugs (adapted from 
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4.2.1 Pharmacokinetics of repaglinide 
After oral administration, repaglinide is rapidly absorbed, and Cmax is reached in 
approximately 1 h.158,159 Oral bioavailability of repaglinide is about 60% (range 
56 to 63%) due to considerable first-pass metabolism.2,160 The elimination of 
repaglinide is also rapid, its terminal elimination t½ is about 1 h.2,159 Cmax and 
AUC of repaglinide increase dose-dependently in patients with type 2 DM 
receiving doses ranging from 0.125 to 16 mg, but tmax remains similar 
irrespective of the dose.2 The interindividual variation in repaglinide AUC is 30 to 
70%, whereas intraindividual variation is lower.2  Repaglinide is highly bound to 
plasma proteins (>98%), mainly to albumin.161  
Repaglinide is extensively metabolised, and only <2% of the dose is excreted 
unchanged in humans.5 The metabolism of repaglinide produces inactive 
metabolites, which are excreted mainly into bile (about 90% of the dose) and to 
a lesser extent into urine (about 8%).5 In humans, the main metabolites of 
repaglinide are M2 (about 68% of the dose), M1 (about 4%) and M4, while other 
metabolites are produced only in very small amounts.5 The most important 
enzymes participating in the biotransformation of repaglinide in vitro are CYP2C8 
and CYP3A4. In vitro, both CYP2C8 and CYP3A4 have been shown to catalyse the 
biotransformation of repaglinide to its major in vivo metabolites, with M1 and M2 
mainly formed by CYP3A4 and M4 mainly by CYP2C8.7 Furthermore, repaglinide 
is not a substrate for P-glycoprotein, according to an unpublished study 
conducted by Novo Nordisk A/S.162    
In vivo (in rat, mouse, rabbit, dog, monkey, and humans), numerous repaglinide 
metabolites have been identified: repaglinide can be metabolised by formation of 





an aromatic amine (M1), opening of the piperadine ring to form a dicarboxylic 
acid (M2), hydroxylation of the piperadine ring (M4), de-ethylation (M5), 
formation of a tauride (M6), formation of an acylglucuronide (M7), and by N-
oxidation (M12).162 M1 can be formed directly from repaglinide, or by oxidative 
N-dealkylation from M2.162 In vitro, repaglinide (M0) can also be metabolised to 
M0-OH (Figure 3).7  
Figure 3. The main biotransformation pathways of repaglinide (22 µM) in vitro, as 















































Age has not significantly influenced repaglinide pharmacokinetics, but compared 
to healthy elderly volunteers, elderly type 2 diabetics have had higher 
repaglinide AUC and Cmax values. Compared to volunteers with normal hepatic 
function, the AUC, Cmax and t½ of repaglinide have been significantly higher in 
those with liver disease. Mild to moderate renal impairment has not significantly 
increased repaglinide AUC in diabetic patients or in otherwise healthy volunteers, 
but severe renal impairment has caused significant increases in repaglinide 
AUC.2   
Polymorphism in the gene encoding CYP2C8 has been associated with altered 
repaglinide pharmacokinetics. Surprisingly, repaglinide (0.25 mg dose) mean 
AUC was 30-50% lower in subjects with the CYP2C8*1/*3 genotype (n=10) 
compared with those with the CYP2C8*1/*1 genotype (n=41),163,164 although in 
another study where a 2 mg repaglinide dose was used no association was found 
(CYP2C8*1/*3 n=11; *1/*1 n=24).165 Incidentally, there is a strong association 
between the major variant alleles of CYP2C8 and CYP2C9 (CYP2C8*3 and 
CYP2C9*2).166     
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4.2.2 Pharmacodynamics of repaglinide 
The pharmacodynamic mechanism of action of repaglinide is to increase insulin 
secretion from pancreatic ß cells. Repaglinide binds to (and closes) the ATP-
sensitive K+ channels on the plasma membrane of ß cells, causing depolarisation 
of the cell without entering it. Depolarisation opens voltage-gated Ca++-channels, 
leading to influx of Ca++ ions and triggering the release of insulin by exocytosis 
(Figure 4). Sulphonylureas and  repaglinide both act by closing the same ion 
channels, but their binding sites within the protein are different.2,167    
Repaglinide does not stimulate insulin release in the absence of glucose, and its 
effect is dependent on the ß cell secretory capacity. The peak serum insulin 
concentrations are reached in 2 to 2.5 hours and maximum hypoglycaemic 
activity in 3 to 3.5 hours, following administration of a single oral dose of 
repaglinide.2   
Figure 4. The pharmacodynamic mechanism of repaglinide. 
3: Ca++ channels are 
















4.2.3 Therapeutic use of repaglinide 
Repaglinide is aimed to be used in patients with type 2 DM, whose blood glucose 
is not adequately controlled by diet and exercise alone. Repaglinide dosage is 
determined individually, and dose titration requires monitoring of fasting and/or 
postprandial blood glucose levels. Repaglinide is administered before each main 
meal, and the recommended starting dose is 0.5 mg per meal. A higher starting 
dose (1 or 2 mg) can be used in patients with HbA1C levels over 8%. The 
maximum recommended single dose is 4 mg, and the total daily dose should not 
exceed 16 mg.1,2  
Placebo-controlled studies have demonstrated the antidiabetic efficacy of 
repaglinide monotherapy, and improvements have been shown in all indicators 
of blood glucose control.168-171  Compared to other oral antidiabetic drugs, the 
efficacy of repaglinide has been equal to that of metformin170,172  and 
glibenclamide.173 Combination therapy with repaglinide and metformin,172  
pioglitazone,20 or rosiglitazone3 has been shown to be more effective than the 
respective monotherapies. Results from one cohort study showed that switching 





to repaglinide from other oral hypoglycaemic agents improved patient eating 
patterns, as the diminished fear of hypoglycaemia reduced snacking between 
meals.174 However, the frequent dosing regimen of repaglinide can also be 
viewed as a disadvantage, and its effectiveness in reducing long-term vascular 
complications of type 2 DM has not been established.  
4.2.4 Adverse effects of repaglinide 
Adverse events occurring during repaglinide therapy, most commonly 
hypoglycaemia, are similar to those caused by suphonylurea treatment, and in 
general mild to moderate in intensity. The incidence of hypoglycaemia has been 
significantly higher in those receiving repaglinide than placebo, but similar for 
repaglinide and sulphonylurea recipients. Serious and nocturnal hypoglycaemias 
have occurred more often with sulphonylureas than with repaglinide, but when 
repaglinide is used in combination with metformin, glitazone or bed-time insulin 
the risk of hypoglycaemia is increased compared to repaglinide monotherapy. 
Upper respiratory tract infections have been reported to be the second most 
common adverse effect of repaglinide treatment. Furthermore, headache, 
gastrointestinal effects, and musculoskeletal pain have been described in 
repaglinide users, but they have occurred with a similar incidence also in placebo 
recipients.1   
4.2.5 Drug interactions of repaglinide 
The effect of CYP inhibition and induction on the pharmacokinetics of repaglinide 
has been studied in several cross-over studies in healthy volunteers. The CYP3A4 
inhibitors clarithromycin, itraconazole, and ketoconazole have all been shown to 
moderately increase repaglinide plasma concentrations.8,9,12 Clarithromycin and 
itraconazole increased repaglinide AUC by about 40%,8,9 ketoconazole by 15%.12   
Gemfibrozil, a CYP2C8 inhibitor, has increased repaglinide AUC 8-fold, 
considerably prolonging and enhancing the blood glucose-lowering effect of 
repaglinide.9  Combination of gemfibrozil and itraconazole has caused a nearly 
20-fold increase in repaglinide AUC, and further enhanced the blood glucose-
lowering effect of repaglinide.9 In patients taking both gemfibrozil and 
repaglinide, events of serious hypoglycaemia have been reported, and their 
concomitant use has been contraindicated by EMEA.175 
The CYP3A4 inducer rifampicin has decreased repaglinide plasma concentrations, 
and similar effects can be expected with other inducers of CYP3A4. In one study, 
where repaglinide was administered 12h after the last rifampicin pre-treatment 
dose, repaglinide AUC was reduced by 57%,10 whereas in another study where 
repaglinide was administered simultaneously with the last rifampicin dose a 31% 
reduction of repaglinide AUC was seen.12 Possible drug interactions between 
repaglinide and CYP inhibitor cimetidine, CYP3A4 substrates ethinylestradiol (also 
a CYP2C9 and CYP2C19 inhibitor),176 simvastatin and nifedipine, and drugs with 
narrow therapeutic margin (digoxin, theophylline or warfarin) have also been 
investigated, but no significant pharmacokinetic changes were observed.12,177    
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5 Drugs studied with repaglinide in vivo 
5.1 Bezafibrate and fenofibrate (Study II) 
Fibrates (bezafibrate, fenofibrate and gemfibrozil) are agonists of the nuclear 
transcription factor PPAR-α, expressed in metabolically active tissues (e.g. liver, 
kidney, heart). They alter the regulation of lipid metabolism, leading to increased 
fatty acid intake into cells and their subsequent oxidation. Fibrates reduce 
plasma triglyceride levels by about 25-50%, LDL-levels only slightly, and usually 
raise HDL-levels by about 10-15%.178  
Fibrates are used primarily in the treatment of hypertriglyceridemia, and as 
second-line agents in hypercholesterolic patients intolerant of statins. Bezafibrate 
is given as a single daily dose of 400 mg, or 200 mg 2-3 times daily, depending 
on the tablet properties. Fenofibrate is given as a single daily dose, or divided 
doses, depending on the formulation. Dose is adjusted according to response, 
usually between 200 and 400 mg daily (Table IV).178  
The most common adverse reactions of bezafibrate and fenofibrate are 
gastrointestinal disturbances such as anorexia, nausea and gastric discomfort. 
Other adverse effects reported to occur less frequently include headache, 
dizziness, vertigo, fatigue, skin rashes, and pruritus. Bezafibrate and fenofibrate 
may enhance the effects of oral anticoagulants and the dose of anticoagulants 
should be reduced when treatment with a fibrate is started.178   
5.2 Trimethoprim (Study III) 
Trimethoprim is a dihydrofolate reductase inhibitor, it inhibits the synthesis of 
bacterial DNA, and acts in the same bacterial metabolic pathway as the 
sulphonamides. Trimethoprim is active against a wide range of Gram-negative 
and Gram-positive aerobes, as well as some protozoa, but anaerobic species are 
usually resistant.179  
Trimethoprim is primarily used for the treatment and prevention of urinary-tract 
infections, but it is used also in gastroenteritis and respiratory tract infections. 
Trimethoprim can be combined with sulphonamides, most commonly with 
sulfamethoxazole. The usual adult dose of trimethoprim in acute infection is 100- 
200 mg twice daily orally, or 200-300mg once daily (Table IV). Trimethoprim is 
well tolerated in general; the most often reported adverse effects are pruritus, 
skin rash, and mild gastrointestinal disturbances.180 Trimethoprim may increase 
the concentrations and potentiate the effects of several drugs, e.g. phenytoin, 
digoxin and procainamide.181  Trimethoprim is a selective inhibitor of CYP2C8 in 
vitro,17 and has been shown to increase rosiglitazone concentrations in vivo.182   
5.3 Cyclosporine (Study IV) 
Cyclosporine is a powerful immunosuppressant, which acts mainly on 
lymphocytes (helper T-cells). By inhibiting the activation of calcineurin, 
cyclosporine decreases the production of lymphokines and depresses the cell-
mediated immune response. Cyclosporine has been the cornerstone of organ and 
tissue transplantation, where it is used in the prevention and management of 
graft rejection. Corticosteroids and/or other immunosupressants are usually used 





with cyclosporine. It is also used in severe forms of atopic dermatitis, psoriasis, 
and rheumatoid arthritis.183  
In organ transplantation, the usual initial dose is 10 to 15 mg/kg daily, and in 
psoriasis, atopic dermatitis, or rheumatoid arthritis approximately 2.5 mg/kg 
daily, reduced gradually to the lowest effective maintenance dose (Table IV). 
Monitoring of cyclosporine concentrations is usually used to guide its dosing, 
particularly when higher doses are used, and monitoring of renal and hepatic 
function, blood pressure and serum electrolytes is also required.184  
Nephrotoxicity is the major adverse effect of cyclosporine treatment, occurring in 
about 1/3 of the patients during long-term treatment. Other frequent adverse 
effects include hypertension, gastrointestinal disturbances, hepatotoxicity, 
headaches, muscle cramps and gingival hyperplasia. There is an increased 
incidence of malignancies and predisposition to infections in patients receiving 
long-term cyclosporine therapy.185,186 Cyclosporine is a CYP3A4 substrate, and 
cyclosporine concentrations may be affected by inducers or inhibitors of CYP3A4. 
In vitro, cyclosporine potently inhibits the transporter proteins P-glycoprotein 
and OATP1B1, and it moderately inhibits CYP3A4.22,187 In vivo, cyclosporine has 
raised the plasma concentrations of several statins, at least partially by inhibiting 
their OATP1B1-mediated hepatic uptake.188   
5.4 Telithromycin (Study V) 
Telithromycin is a bactericidal ketolide antimicrobial agent. It is highly active 
against Gram-positive bacteria such as streptococci, including S. pneumoniae 
and S. pyogenes, and also shows good activity against Gram-negative organisms 
H. influenzae and M. catarrhalis.189 Telithromycin is used for the treatment of 
respiratory tract infections, given orally in a usual dose of 800 mg once daily 
(Table IV). The most common adverse effects of telithromycin are diarrhoea and 
other gastrointestinal disturbances. Elevation of liver enzymes and cholestatic 
jaundice has also occurred during telithromycin treatment, and other effects less 
commonly reported include dizziness, headache, and drowsiness.190,191 
Telithromycin inhibits CYP3A4 and CYP2D6 in vitro, and it can considerably raise 
the plasma concentrations of CYP3A4 substrates also in vivo. For example, the 
AUC of simvastatin is raised about 10-fold by telithromycin.192   
5.5 Montelukast (Study V) 
In the pathophysiology of asthma, cysteinyl leukotrienes released from mast 
cells and eosinophils cause airway oedema, smooth muscle contraction, and alter 
inflammatory processes. By binding to the cysteinyl leukotriene receptor, 
montelukast inhibits the actions of cysteinyl leukotrienes, and helps to relieve 
the symptoms of asthma.193 Montelukast is used in the management of chronic 
asthma, usually in addition to inhaled corticosteroids, and seasonal allergic 
rhinitis, given in daily doses of 10 mg (Table IV). Montelukast has no use in the 
treatment of acute asthma attacks. Headaches, increased incidence of 
respiratory tract infections and GI disturbances have been reported with 
montelukast. Other adverse effects include myalgia, fever, dizziness, elevations 
in liver enzymes and hypersensitivity reactions.194-196 Phenobarbital has 
decreased the AUC of single-dose montelukast about 40%, but montelukast has 
not altered the pharmacokinetics of coadministered warfarin or digoxin.197,198 
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Montelukast is a potent and selective inhibitor of CYP2C8 in vitro, and depending 
on microsomal protein concentration its Ki for CYP2C8 has ranged from 0.0092 
to 0.15 µM.16   
5.6 Pioglitazone (Study VI) 
The antidiabetic pioglitazone is an insulin-sensitising agent that acts by 
activating the nuclear receptor a PPAR-γ, and gradually decreases insulin 
resistance in muscle, adipose tissue and liver by altering glucose metabolism. 
Pioglitazone has also been found to reduce triglyceride levels and increase HDL 
concentrations.199 In patients with type 2 diabetes, pioglitazone is given orally as 
monotherapy, or combined to metformin, sulphonylurea, or a meglitinide, when 
monotherapy is inadequate. The usual dose is 15 or 30mg once daily, increased 
to a maximum of 45mg if necessary (Table IV).200  Pioglitazone may cause 
hypoglycaemia, headache, weight gain, and anemia; other reported adverse 
effects include upper respiratory tract infections, gastrointestinal disturbances, 
dizziness, and pruritus. Pioglitazone can also cause oedema, which can 
precipitate or worsen cardiac failure.200 In vivo, concomitant rifampicin has 
decreased pioglitazone AUC by 54%,201 whereas gemfibrozil has increased 
pioglitazone AUC 3.2-fold.202 In vitro, pioglitazone has been reported to inhibit 
both CYP2C8 and CYP3A4 enzymes.19  Based on these in vitro findings and usual 
plasma concentrations of pioglitazone, it has been estimated that pioglitazone 
would have the potential to inhibit CYP2C8 also in vivo.19    
















Bezafibrate178,203  100%         
(1 to 2 h) 
95% 1.5 to 3 h Mainly in urine, 
about 50% 
unchanged, 50% as 
metabolites; a 
fraction in faeces 
 
Fenofibrate178,204  60%               
(-) 




to the active 
compound fenofibric 
acid 
Trimethoprim180 >90%           
(1 to 4 h) 
45% 8 to 10 h Mainly in urine, 40 
to 60% unchanged 
 
Cyclosporine183    
(microemulsion)  
40%             
(1½ to 2 h) 
90% 5 to 20 h Mainly via bile into 
faeces as 
metabolites, 6% in 
urine 
In blood, about 50% 
is in erythrocytes, 
about 15% in 
leukocytes, remainder 
in plasma 
Telithromycin192 60%           
(1 to 3 h) 
65% 8 to 13 h Via bile into faeces 
and in urine, about 
2/3 as metabolites 
and 1/3 unchanged 
 
Montelukast205 64%           
(2 to 4 h) 
>99% 5 to 7 h Via bile into faeces 
as metabolites 
 
Pioglitazone200,206 >80%        
(1 to 2 h) 
>99% 4 to 9 h Via bile into faeces 
and in urine as 
metabolites 
The t½ of pioglitazone 
metabolites is up to 
24 h 
tmax, time to peak concentration; t½, half-life. 
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A I M S   O F   T H E   S T U D Y 
 
The aims of this thesis work were to investigate the relative contributions of 
CYP2C8 and CYP3A4 in the metabolism of repaglinide, potential drug interactions 
of repaglinide, and their mechanisms. 
Specific aims of the studies were: 
I To investigate the relative contributions of CYP2C8 and CYP3A4 in the 
metabolism of repaglinide, and to study the effects of bezafibrate, 
fenofibrate, gemfibrozil, and rifampicin on the metabolism of 
repaglinide and CYP2C8 and CYP3A4 activities in vitro.  
II To investigate the effects of bezafibrate and fenofibrate on the 
pharmacokinetics and pharmacodynamics of repaglinide in vivo, in 
order to compare their interaction potential with repaglinide to that of 
gemfibrozil. 
III To investigate the effects of trimethoprim, a selective CYP2C8 
inhibitor on the pharmacokinetics and pharmacodynamics of 
repaglinide in vivo, and the effects of trimethoprim on the metabolism 
of repaglinide by HLM in vitro. 
IV To investigate the effects of cyclosporine, an inhibitor of CYP3A4 and 
OATP1B1, on the pharmacokinetics and pharmacodynamics of 
repaglinide in vivo, to determine the effect of cyclosporine on the 
metabolism of repaglinide in vitro, and to study the effect of genetic 
variation (selected CYP enzymes and drug transporters) on the extent 
of possible interaction. 
V To investigate the effects of telithromycin (CYP3A4 inhibitor in vivo 
and in vitro), montelukast (potent CYP2C8 inhibitor in vitro), and their 
combination on the pharmacokinetics, pharmacodynamics and 
metabolic fate of repaglinide in vivo. 
VI To investigate the effects of pioglitazone (CYP2C8 and CYP3A4 
inhibitor in vitro) on the pharmacokinetics and pharmacodynamics of 
repaglinide in vivo, in order to clarify whether their synergistic effect 
in diabetic patients is caused by inhibition of repaglinide metabolism 
by pioglitazone. 




M A T E R I A L S   A N D   M E T H O D S 
1 In vitro studies 
Using human liver microsomes and recombinant CYP enzymes, the details of 
repaglinide metabolism, and the effects of potential metabolic inhibitors on 
repaglinide metabolism and CYP marker reactions were studied in vitro.  
In study I, the relative contributions of CYP2C8 and CYP3A4 to repaglinide 
metabolism, and the effect of fibrates and rifampicin on repaglinide metabolism 
and CYP2C8 and CYP3A4 activities were investigated. The effect of trimethoprim 
on repaglinide metabolism was determined in study III. In study IV, the effect of 
cyclosporine on the metabolism of repaglinide to M1, M2, and M4, as well as the 
contributions of CYP2C8 and CYP3A4 to the formation of these metabolites was 
investigated. 
1.1 Design of in vitro studies 
The in vitro incubations were conducted in duplicate in a shaking water bath at 
37 °C, and the incubation times and microsomal protein concentrations (HLM 
and rhCYP) were within the linear range for reaction velocity. In inhibition 
studies, preincubation assays were conducted to assess possible metabolism-
dependent inhibition. Intra-assay coefficient of variation (CV) was less than 15% 
for the duplicates, and mean values were used in the calculations. The 
incubations were carried out in 0.1 M sodium phosphate buffer (pH 7.4), 
containing 5.0 mM MgCl2. The stock solutions of all the drugs were prepared in 
methanol (final concentration 1% v/v in the incubation mixture). The drug(s), 
buffer, and microsomes were premixed and incubations were commenced by the 
addition of ß-NADPH (final concentration 1.0 mM), and quenched depending on 
the substrate used. The microsomes were vortexed each time before dilution, 
and the incubation mixtures were vortexed at the start and end of each 
incubation. Preliminary assays were conducted to determine appropriate 
microsomal protein concentrations, and rhCYP concentrations with corresponding 
reaction velocities. 
1.1.1 HLM and rhCYPs 
The pooled human liver microsomes (HLM) were purchased from Gentest Corp 
(Woburn, MA, USA). Human liver tissue had been collected in the USA in 
accordance with all pertinent regulations, and permissions from the donors’ 
families had been obtained prior to organ collection. The procedures of organ 
collection had been accepted by the respective institutional Human Subjects 
Committee, and liver samples were mostly from Caucasian subjects. 
Recombinant human CYP2C8 and CYP3A4 (Supersomes™) from baculovirus-
infected insect cells were purchased from Gentest. HLM and recombinant CYPs 
were kept at -70ºC until use, thawed in a water bath and placed on ice, and 
diluted as appropriate before addition into the incubation mixture. Incubation 
mixtures and diluted mixtures were kept on ice until the incubations were 
started. The HLM system was used in studies I, III, and IV, the rhCYP system 
was used in studies I and IV.  
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1.1.2 Metabolism of repaglinide by HLM, CYP2C8 and CYP3A4 
REPAGLINIDE DEPLETION (I) To determine the apparent kinetic constants (Km and 
Vmax), the metabolism of repaglinide was studied in HLM and rhCYPs using the 
substrate depletion method. Varying concentrations of repaglinide were 
incubated with HLM (0-150 µM), rhCYP2C8 (0-50 µM) and rhCYP3A4 (0-80 µM), 
and the amount of unchanged repaglinide was measured from samples taken 0, 
10, 20 and 30 min from the start of the incubation. 
FORMATION OF REPAGLINIDE METABOLITES M1, M2, AND M4 (IV) To determine the 
contribution of CYP2C8 and CYP3A4 to the formation of repaglinide metabolites 
M1, M2, and M4, repaglinide (2 µM) was incubated with rhCYP2C8 and 
rhCYP3A4. Reaction velocity was determined from the amount of metabolite 
formed. 
1.1.3 Inhibition of repaglinide metabolism, CYP2C8 and CYP3A4 
EFFECT OF CYP2C8 AND CYP3A4 INHIBITION ON REPAGLINIDE METABOLISM IN HLM 
(I) This assay was designed to determine the effect of inhibition of CYP2C8, 
CYP3A4 and both CYP2C8 and CYP3A4 to the metabolism of repaglinide in HLM. 
Quercetin (25 µM, CYP2C8 inhibitor), itraconazole (3 µM, CYP3A4 inhibitor), their 
combination and vehicle only were incubated with repaglinide (0.2 and 2 µM). 
These inhibitor  concentrations were estimated to cause at least 80% inhibition 
of respective enzyme activities.101,207,208 Substrate depletion method was used, 
as described above, and inhibition described as percentage of control activity. 
EFFECT OF FIBRATES AND RIFAMPICIN ON REPAGLINIDE METABOLISM IN HLM (I) 
Repaglinide (2 µM) was incubated with bezafibrate (0-80 µM), fenofibrate (0-200 
µM), gemfibrozil (0-200 µM) and rifampicin (0-120 µM) to determine their 
respective effects on the metabolism of repaglinide in HLM. Substrate depletion 
method was used, as described above, and inhibition described by IC50 values.  
EFFECT OF FIBRATES AND RIFAMPICIN ON CYP2C8 AND CYP3A4 IN HLM (I) The effect 
bezafibrate (0-60 µM), fenofibrate (0-150 µM), gemfibrozil (0-160 µM) and 
rifampicin (0-260 µM) on the marker reactions of CYP2C8 (paclitaxel 6α-
hydroxylation) and CYP3A4 (midazolam 1α-hydroxylation) were investigated in 
HLM. Reaction velocities were determined from the amount of metabolite 
formed, and Ki values were determined when inhibition was observed.  
EFFECT OF TRIMETHOPRIM ON REPAGLINIDE METABOLISM IN HLM (III) The effect of 
trimethoprim (0-200 µM) on the metabolism of repaglinide (0.22 µM) was 
studied in HLM, and IC50 value was determined. Substrate depletion method was 
used as described above, but samples were taken at 0, 15, and 30 min from the 
start of the incubation.  
EFFECT OF CYCLOSPORINE ON REPAGLINIDE METABOLISM IN HLM (IV) The effect of 
cyclosporine (0-30 µM) on the formation of M1, M2, and M4 metabolites of 
repaglinide (2 µM) was studied in HLM. Reaction velocity was determined from 
the amount of metabolite formed, and IC50 values were determined when 
inhibition was observed.  




1.2 Determination of drug concentrations 
REPAGLINIDE The concentrations of repaglinide (and its metabolites in IV) were 
measured using either high-performance liquid chromatography with ultraviolet 
detection (HPLC-UV), or liquid chromatography-tandem mass spectrometry (LC-
MS-MS) (in the low-concentration kinetic studies and the inhibition studies with 
rifampicin, quercetin, and itraconazole). Repaglinide metabolite concentrations 
were given in arbitrary units (units per mL) relative to the ratio of the peak 
height of each metabolite to that of the internal standard in the chromatogram. 
In the HPLC analysis, ibuprofen served as internal standard, and quantification 
was performed with UV-detection at 243 nm. The limit of quantification for 
repaglinide was 0.1 µM, and the day-to-day CVs were <6% at relevant 
concentrations. In the LC-MS-MS analysis, PE SCIEX API 3000 liquid 
chromatography-tandem mass spectrometry system (Sciex Division of MDS Inc, 
Toronto, Ontario, Canada) was used and nateglinide served as internal standard. 
The mass spectrometer was operated in the turbo ion spray mode with positive 
ion detection and the ion transitions monitored were those representing the 
product ions of the [M+H]+ ions. The limit of quantification for repaglinide was 5 
nM and the CVs were <10% at relevant concentrations.  
1-OH MIDAZOLAM To measure 1-OH midazolam concentrations, HPLC-analysis 
with UV-detection at 245 nm was used.209 The limit of quantification for 1-OH 
midazolam was 10 nM, and the CVs were <8% at relevant concentrations.  
6-OH PACLITAXEL 6-OH Paclitaxel concentrations were measured with HPLC-UV210 
or LC-MS-MS211 (the inhibition study with rifampicin). In the HPLC analysis, UV-
detection at 230 nm was used and the limit of quantification for 6-OH paclitaxel 
was 50 nM; the CVs were <7% at relevant concentrations. In the LC-MS-MS 
analysis, PE SCIEX API 2000 liquid chromatography tandem mass spectrometry 
system (Sciex Division of MDS Inc) was used and docetaxel served as internal 
standard. The limit of quantification for 6-OH paclitaxel was 25 nM, and the CVs 
were <8% at relevant concentrations. 
1.3 Data analysis 
SUBSTRATE DEPLETION METHOD For each substrate concentration (and inhibitor 
concentration, when applicable), pseudo-first order rate constants (k) for 
repaglinide metabolism were determined from the concentration-time points. k 
was calculated by linear regression from the natural logarithm of repaglinide 
concentration versus incubation time using the program MK-model (version 5.0, 
Biosoft, Cambridge, UK). The initial reaction velocity (v0) was calculated by the 
equation v0 = C0 · k, where C0 is the initial concentration of repaglinide.  
Reaction velocities were expressed as pmol/min/mg protein or pmol/min/pmol 
CYP. IC50, Km and Vmax values were determined from reaction velocity data by 
nonlinear regression analysis using the program Fig.P (version 6.0, Biosoft, 
Cambridge, UK); simple Michaelis-Menten kinetic model was the best to fit the 
data.  
METABOLITE FORMATION METHOD Reaction velocities were calculated for the 
CYP2C8 and CYP3A4 marker reactions (I) and formation of repaglinide 
metabolites (IV). The Ki values were determined by nonlinear regression analysis 
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using the program SigmaPlot (version 8.0, SPSS Inc., Chicago, IL, USA). 
Lineweaver-Burk and Dixon plots of the data were used to determine the type of 
inhibition; the model for competitive inhibition was the best to fit the data. IC50 
values were determined by nonlinear regression analysis using the program 
Fig.P. 
CALCULATIONS Intrinsic clearance (CLint) values for the metabolism of repaglinide 
by rhCYPs and HLM were calculated by the equation CLint = Km / Vmax. The relative 
activity factor (RAF, describing the amount of rhCYP required for equal reaction 
velocity per mg of HLM) was calculated for CYP2C8 and CYP3A4 using activity 
data provided by Gentest. 
The relative contributions of CYP2C8 and CYP3A4 in the in vivo hepatic 
metabolism of repaglinide were estimated by multiplying recombinant enzyme 
CLint values with the respective RAF. The relative contributions of CYP2C8 and 
CYP3A4 in the hepatic metabolism of repaglinide were also estimated from the 
CLint values using CYP enzyme abundances in HLM and intersystem extrapolating 
factors (ISEF) for rhCYPs and HLM.147 The CLint determined in HLM was 
expressed per kilogram body weight using standard scaling factors.148,149 Hepatic 
blood clearance (CLh) value was estimated using the well stirred model: CLh = Q· 
fu · CLint / (Q · fu · CLint)150 where Q is the hepatic blood flow and fu is the 
unbound fraction (0.015) of repaglinide in blood.161   
  




2 In vivo studies 
A total of five in vivo studies were conducted in healthy human volunteers to 
investigate the effects of bezafibrate, fenofibrate, trimethoprim, cyclosporine, 
telithromycin, montelukast, and pioglitazone on the pharmacokinetics and 
pharmacodynamics of repaglinide. 
The studies were carried out in the facilities of the Department of Clinical 
Pharmacology, University of Helsinki.  The study protocols were approved by the 
Ethics Committee for Studies in Healthy Subjects and Primary Care (Hospital 
District of Helsinki and Uusimaa) and by the Finnish National Agency for 
Medicines. Before entering the studies the volunteers had given their written 
informed consent, and were ascertained to be healthy by medical history, 
physical examination, and routine laboratory tests. 
2.1 Design of in vivo studies 
The studies were randomised, placebo-controlled, cross-over studies, which 
consisted of 2 to 4 phases (Figure 5). In each phase, a pre-treatment period with 
the study drug or placebo was followed by the study day, when repaglinide was 
ingested. Following an overnight fast, 0.25 mg repaglinide was ingested with 150 
mL water at about 9.00, and the volunteers spent the next 3 h seated. During 
the study days, timed blood samples were taken for monitoring of blood glucose 
levels and for determination of drug concentrations. In studies IV and V, urine 
was collected cumulatively for 12 h after repaglinide administration for the 
quantification of repaglinide and metabolite excretion.  During the study days, 
the volunteers were under direct medical supervision, and food intake was 
strictly controlled. Between the phases was a 2 or 4 week wash-out period. 
The pre-treatment medications (Table V) and matched placebos were supplied, 
packed, and labelled according to a randomisation list for each subject by the 
Pharmacy of the Helsinki University Central Hospital, which supplied also 
repaglinide used in studies. 
2.2 Subjects 
57 subjects (50 male, 7 female) healthy volunteers participated in the studies 
(Table VI). None of the subjects used continuous medication (not even oral 
contraceptives), and use of grapefruit juice or any pharmaceuticals was not 
allowed for 2 weeks before the study. Participation in other studies and donation 
of blood were not allowed for one month before and after the study. The main 
exclusion criteria for the studies were: a history of intolerance to the study 
drugs, concomitant drug therapy of any kind, an existing disease of possible 
significance, age <18 or >45 years, a history of haematological, endocrine, 
metabolic, or gastrointestinal disease, pregnancy or nursing.  
2.3 Blood sampling 
On the days of repaglinide administration, timed blood samples (10 mL each) 
were drawn from a cannulated forearm vein and collected into tubes containing 
ethylenediaminetetra-acetic acid (EDTA) (Table VII). Blood glucose 
concentrations were measured immediately after each blood sampling by the 
glucose oxidase method (Precision G Blood Glucose Testing System, Medisense, 
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Bedford, MA, USA). Plasma was separated within 30 min after blood sampling, 
and samples were stored at -70 ºC until analysis. 
 
Figure 5. The overall design of the in vivo studies. 
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Table V. The formulations and manufacturers of drugs used in studies II-VI. 
Drug Medicinal product Manufacturer 
Repaglinide NovoNorm 0.5 mg tablet (halved) Novo Nordisk, Bagsvaerd, Denmark 
Bezafibrate Bezalip 400 mg tablet Roche, Mannheim, Germany 
Fenofibrate Lipanthyl 200 mg capsule Fournier S.A., Fontaine Les Dijon, France 
Trimethoprim Trimetin 160 mg tablet Vitabalans, Hämeenlinna, Finland 
Cyclosporine Sandimmun Neoral 100 mg capsule Novartis Pharma SA, Huningue, France 
Telithromycin Ketek 400 mg tablet Aventis Pharma, Scoppito, Italy 
Montelukast Singulair 10 mg  tablet Merck, Sharp & Dohme, Haarlem, Holland 
Pioglitazone Actos 30 mg capsule Lilly, Madrid, Spain 
 




Table VI. The characteristics of subjects, pre-treatment medication, and wash-out period 





















 II 12 (12/0) 21-26 58-100 Placebo, bezafibrate (400 mg)  or 
fenofibrate (200 mg) at 08 for 5 days 
2 
 III 9 (8/1)* 19-23 62-97 Placebo or trimethoprim (160 mg) at 08 and 
20 for 3 days  
2 
 IV 12 (12/0) 19-25 56-100 Placebo or cyclosporine (100 mg) for 2 days 
(at 20 on day 1 and 08 on day 2) 
4 
 V 12 (8/4) 18-24 52-85 Placebo, telithromycin (800 mg), 
montelukast (10 mg), or telithromycin and 
montelukast at 08 for 3 days 
2 
 VI 12 (10/2) 21-28 57-100 Placebo or pioglitazone (30 mg) at 08 for 5 
days  
4 




Table VII. Repaglinide administration, food intake, and timing of blood samples in the 
studies conducted in healthy volunteers (II-VI). 
 
 
Repaglinide (0.25 mg) administered at 09 with 150 mL water, following an overnight fast 
 
Food intake after repaglinide ingestion: 
     15 min:    a light standard breakfast (eaten in 10 min) 
     1 h:         a standard snack (eaten in 5 min) 
     2 h:         a standard snack (eaten in 5 min) 
     3 h:         a personalised standard warm meal (eaten in 30 min) 
     7 h:         a personalised standard light meal (eaten in 30 min) * 
     12 h:       a personalised standard snack (eaten in 20 min) * 
 
Blood samples were taken prior to, and 20, 40, 60, 80, and 100 min and 2, 2½, 3, 4, 5, 7, 
9,* and 12 h* after the administration of repaglinide 
 
     *  Not in studies II and III, where the study day ended 7 h  after repaglinide ingestion. 
 
2.4 Determination of drug concentrations 
The concentrations of repaglinide, its metabolites and pretreatment drugs were 
determined using a liquid chromatography-tandem mass spectrometry (LC-MS-
MS) system, HPLC with ultraviolet or fluorescence detection, and in the case of 
cyclosporine, a commercially available radioimmunoassay (CYCLO-Trac; 
Diasorin, Stillwater, Minn, USA). The mass spectrometer used was a PE SCIEX 
API 3000 mass spectrometer (Sciex Division of MDS Inc, Toronto, Ontario, 
Canada), and the ion transitions monitored for repaglinide were m/z 453 to m/z 
230 (Table VIII).  
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Table VIII. The quantification of analytes in studies II-VI.  
Study Analytes quantified  Method used Limit of 
quantification 
Between-
day CV # 
II Repaglinide LC-MS-MS 0.05 ng/mL <10% 
 Bezafibrate HPLC-UV 0.1 mg/mL <9% 
 Fenofibrate HPLC-UV 0.1 mg/mL <11% 
III Repaglinide and M1*  LC-MS-MS 0.1 ng/mL <14% 
 Trimethoprim  HPLC-UV 0.1 mg/mL <5% 
IV Repaglinide, M1, M2, and M4* LC-MS-MS 0.02 ng/mL <14% 
 Cyclosporine in blood Radioimmunoassay 30 ng/mL <5% 
V Repaglinide, M1, M2, and M4* LC-MS-MS 0.01 ng/mL <10% 
 Montelukast HPLC-fluorescence 5.0 ng/mL <14% 
 Telithromycin LC-MS-MS 5.0 ng/mL <7% 
VI  Repaglinide LC-MS-MS 0.02 ng/mL <13% 





* Limit of quantification is for repaglinide; the limit of quantification for repaglinide metabolites 
could not be determined because authentic reference compounds were not available. Repaglinide 
metabolite concentrations were given in arbitrary units (U/mL) relative to the ratio of the peak 
height of each metabolite to that of the internal standard in the chromatogram. 
# Between-day coefficient of variation (CV) was determined for low, intermediate, and high 
concentration control samples in the relevant concentration range; the highest of the three 
values is presented in the table. 
2.5 Pharmacokinetic calculations 
The pharmacokinetics of repaglinide were characterised by Cmax, tmax, AUC from 
0 to infinity (AUC0-∞) and t½. Cmax and tmax were taken directly from the original 
data. The terminal log-linear part of each concentration-time curve was 
identified visually, and ke was determined from log-transformed data using linear 
regression analysis. t½ was calculated by the equation t½=ln(2)/ke. The AUC 
values were calculated by use of the linear trapezoidal rule for the rising phase 
of the plasma concentration-time curve and the log-linear trapezoidal rule for the 
descending phase, with extrapolation to infinity, when appropriate, by dividing 
the last measured concentration by ke. The pharmacokinetics of repaglinide 
metabolites and pre-treatment drugs were determined similarly, but their 
concentrations were measured from fewer samples.  
2.6 Pharmacodynamic variables 
The pharmacodynamics of repaglinide were characterised by the maximum 
increase and maximum decrease from baseline blood glucose concentration, and 
by mean change in blood glucose concentration from baseline, except in study V, 
where maximum, minimum and mean blood glucose concentrations were used. 
The mean change was calculated by dividing the net area under the blood 
glucose concentration-time curve (from 0 to 3 h, 0 to 7 h, and 0 to 12 h) by the 
corresponding time interval. In study V, the mean blood glucose concentration 
was calculated by dividing the area under the blood glucose concentration-time 
curve by the corresponding time interval. 





The subjects that participated in study IV were genotyped for selected SNPs in 
the genes encoding OATP1B1 and P-glycoprotein, as well as for selected CYP2C8 
and CYP3A5 alleles.  
The presence of two SNPs in the gene encoding the hepatic transporter 
OATP1B1, SLCO1B1 (c.-11187G>A in the promoter region and c.521T>C 
[Val174Ala] in exon 5), two SNPS in the gene encoding the transporter MDR1 (P-
glycoprotein), ABCB1 (c.2677G>T/A [Ala893Ser/Thr] in exon 21 and c.3435C>T 
[syn] in exon 26) were analysed. The CYP2C8 and CYP3A5 genotypes were 
determined by investigating the presence of CYP2C8*3 (c.416G>A, 1196 A>G; 
Arg139Lys, Lys399Arg), CYP2C8*4 (792C>G; Ile264Met), and CYP3A5*3 
(6986A>G; nonexpressor) alleles. 
2.8 In vitro-in vivo interaction predictions 
In studies V and VI, the effect of montelukast and pioglitazone on the AUC of a 
CYP2C8 substrate was estimated on the basis of their previously published Ki 
values for CYP2C8. The inhibitor concentration available to the enzyme in vivo 
([I]in vivo) was calculated using following equations:16  
Systemic total Cmax:  [I]in vivo = Cmax 
Systemic free Cmax:  [I]in vivo = fu · Cmax    
Estimated total portal Cmax: [I]in vivo = Cmax + ka · Fa · D / Qh 
Estimated free portal Cmax:  [I]in vivo = fu · (Cmax + ka · Fa · D / Qh) 
where  fu = the unbound fraction of the inhibitor 
 ka = absorption rate constant 
 Fa = oral bioavailability 
 D = dose of the inhibitor 
 Qh = hepatic blood flow 
 
Once the [I]in vivo has been determined, the magnitude of potential interaction 
was estimated using the following estimation, where fm = fraction of the 
























2.9 Statistical analysis 
In the studies with two phases (III, IV and VI), the pharmacokinetic and 
pharmacodynamic variables from the placebo and premedication phases were 
compared using the paired t-test. The tmax values were compared using the 
Wilcoxon signed-rank test. When an interaction was observed, the Pearson 
correlation coefficient was used to investigate the possible relationships of 
pharmacokinetic variables of the premedication drug with the blood glucose-
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lowering response and the extent of interaction. The differences were considered 
statistically significant when P was < .05. For all variables except tmax, 95% 
confidence intervals (CI) were calculated for the mean differences between the 
phases. 
In study IV, possible associations of the investigated SNPs and haplotypes with 
the degree of interaction between cyclosporine and repaglinide were investigated 
using ANOVA, followed by a posteriori testing with the Tukey test. The analysis 
was performed with the statistical programs SYSTAT for Windows (version 6.0.1) 
and SPSS for Windows (version 11.0) (SPSS, Chicago, USA).  
In study II (3 phases), the pharmacokinetic variables were compared by 
repeated-measures analysis of variance (ANOVA), followed by a posteriori 
testing with the paired t-test with the Bonferroni correction for multiple 
comparisons. The Bonferroni correction was used also when analysing tmax values 
with the Wilcoxon signed-rank test. In study V (4 phases) uncorrected P values 
are presented while the threshold for statistical significance with the Bonferroni 
correction is presented separately, as requested by the editor of Clinical 
Pharmacology & Therapeutics. 
  




R E S U L T S   A N D   D I S C U S S I O N 
1 In vitro studies 
1.1 Metabolism of repaglinide by CYP2C8, CYP3A4 and HLM 
Incubation of repaglinide with HLM, rhCYP2C8 and rhCYP3A4 resulted in time- 
and NADPH-dependent substrate consumption. The decline in repaglinide 
concentration was log-linear for at least 30 min, and the rate of metabolism was 
linear with respect to microsomal protein concentration up to at least 0.5 
mg/mL. In the inhibition assays, preincubation with NADPH and HLM was not 
found to increase the observed inhibitory effect.  
The Km, Vmax, and CLint values of HLM, rhCYP2C8 and rhCYP3A4 for repaglinide 
metabolism are presented in Table IX. At concentrations of repaglinide up to 2 
mM, the metabolism rates of the two enzymes were similar, but at higher 
repaglinide concentrations, CYP3A4 was more active than CYP2C8. M1, M2, and 
M4 metabolites of repaglinide were all formed in incubations with both rhCYP2C8 
and rhCYP3A4. M1 and M2 were predominantly formed by recombinant CYP3A4, 
whereas M4 was formed mainly by recombinant CYP2C8. 
The intrinsic clearance (CLint) of repaglinide in HLM was estimated also from 
rhCYP CLint data using the relative activity factor (RAF) calculated from Gentest 
product info, as well as using previously published intersystem extrapolating 
factors (ISEF), determined by comparing activity differences in rhCYPs and HLM. 
The CLint values of repaglinide metabolism were similar for CYP2C8 and CYP3A4, 
when expressed per amount of CYP, as were the RAF-adjusted predictions of 
microsomal CLint. Estimates based on ISEF values and CYP abundances gave 
different results; use of Vmax-based ISEF values predicted CYP2C8 to be more 
important while CLint-based ISEF values predicted CYP3A4 to be more important 
in the metabolism of repaglinide.  
1.2 Inhibition of CYP2C8, CYP3A4 and repaglinide metabolism 
The nonselective CYP2C8-inhibitor quercetin (25 µM), and the selective CYP3A4-
inhibitor itraconazole (3 µM) both inhibited the metabolism of 2 µM repaglinide 
by about 60%, their combination by about 90%. They inhibited the metabolism 
of 0.2 µM repaglinide by about 60% and 70%, respectively, their combination by 
about 90%. Rifampicin was the most potent inhibitor of repaglinide metabolism, 
followed by bezafibrate, trimethoprim, gemfibrozil and fenofibrate. Bezafibrate, 
gemfibrozil and fenofibrate had no effect on CYP3A4-mediated midazolam 1-
hydroxylation, but inhibited CYP2C8-mediated paclitaxel 6-hydroxylation in the 
same order of potency as they inhibited repaglinide metabolism. Rifampicin 
competitively inhibited both CYP3A4 and CYP2C8. Cyclosporine inhibited the 
formation of the repaglinide metabolites formed mainly by CYP3A4 in vitro (M1 
and M2) in HLM, with no effect on the formation of M4 (formed mainly by 
CYP2C8) (Table IX).  
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Table IX. Summary of in vitro findings. The kinetic constants of repaglinide metabolism 
by rhCYP2C8, rhCYP3A4, and HLM (top), and inhibitory constants of studied drugs for 
CYP2C8-activity, CYP3A4-activity and repaglinide (2 µM) metabolism in HLM (bottom). 
Repaglinide metabolism by rhCYP2C8 by rhCYP3A4 by HLM 
Km 2.8 µM 15.6 µM 24.2 µM 
Vmax 4.9 pmol/pmol CYP/min 27.8 pmol/pmol CYP/min 3150 pmol/mg HLM/min 
CLint 1.7 mL/nmol CYP/min 1.8 mL/nmol CYP/min 130 mL/g HLM/min 
CLint (RAF) 55.1 mL/g HLM/min 64.8 mL/g HLM/min - 
CLint (VISEF) 279 mL/g HLM/min 114 mL/g HLM/min - 
CLint (CLISEF) 3.4 mL/g HLM/min 47.7 mL/g HLM/min - 
M1 formation 0.5 U/pmol CYP/min 8.1 U/pmol CYP/min - 
M2 formation 0.03 U/pmol CYP/min 1.0 U/pmol CYP/min - 
M4 formation 6.9 U/pmol CYP/min 0.1 U/pmol CYP/min - 
   
Inhibitory constants in HLM CYP2C8 activity CYP3A4 activity Repaglinide metabolism 
Bezafibrate Ki 9.7 µM - IC50 37.7 µM 
Gemfibrozil Ki 30.4 µM - IC50 111 µM 
Fenofibrate Ki 92.6 µM - IC50 164 µM 
Trimethoprim   Ki 30.4 µM * -     IC50 129 µM ** 
Rifampicin Ki 30.2 µM Ki 18.5 µM IC50 13.7 µM 
Cyclosporine 
     M1 formation 
     M2 formation 










IC50 0.2 µM 
IC50 4.3 µM 
- 
 
*   The Ki of trimethoprim for CYP2C8 is from Wen et al.  
** Repaglinide concentration used to determine IC50 was 0.22 µM. 
1.3 Discussion 
The results from these in vitro studies are of theoretical and practical 
importance. They clarify the roles of CYP2C8 and CYP3A4 enzymes in the overall 
metabolism of repaglinide and the underlying mechanisms explaining the results 
of pharmacokinetic interaction studies with repaglinide.  
The identification of CYP2C8 and CYP3A4 as the most important enzymes 
catalysing the oxidative biotransformation of repaglinide was reported by 
Bidstrup et al.7 The authors reported that the main in vivo metabolites of 
repaglinide, M1 and M2, as well as M5, were predominantly formed by CYP3A4, 
while M4 and M0-OH were mainly formed by CYP2C8. However, only a single 
repaglinide concentration of 22 µM was used in that study, which exceeds over 
100 times its therapeutic plasma concentrations.2 We found that CYP2C8 and 
CYP3A4 metabolised repaglinide with similar reaction velocities at repaglinide 
concentrations up to 2 µM. Furthermore, at supratherapeutic repaglinide 
concentrations, the role of CYP3A4 became greater, which may explain the 
findings favouring the relative importance of CYP3A4 in the metabolism of 
repaglinide.  




Estimations of relative importance of the CYP2C8 and CYP3A4 in repaglinide 
metabolism based on rhCYP CLint values gave different results depending on the 
scaling approach used. When using previously published scaling factors147 based 
on Vmax differences between recombinant CYP and HLM systems, the results 
favoured CYP2C8, but scaling factors based on CLint differences favoured 
CYP3A4. Estimation based on the reaction velocity data provided by the rhCYP 
and HLM manufacturer (Gentest) suggested that the contributions of the two 
enzymes were similar.  
The estimation of the hepatic clearance of repaglinide, based on our HLM CLint 
results, was only 17% of the reported systemic repaglinide clearance.2 This 
underprediction could be explained by e.g. active uptake transport of repaglinide 
into hepatocytes. An approximately 10-fold hepatocyte-to-plasma repaglinide 
unbound concentration ratio, produced e.g. by uptake transporters, would 
correct the estimated systemic clearance. Recently published data strongly 
suggest that repaglinide is a substrate of the hepatic uptake transporter 
OATP1B1.164 SLCO1B1 genotype (encoding OATP1B1) has been shown to 
influence repaglinide baseline AUC, as well as the degree of interaction between 
repaglinide and cyclosporine (IV), an OATP1B1 (and CYP3A4) inhibitor.22,187,188   
In vitro in HLM, CYP2C8 inhibitors bezafibrate, fenofibrate, gemfibrozil, and 
trimethoprim, CYP3A4 inhibitor cyclosporine were all shown to inhibit repaglinide 
metabolism. Furthermore, similar inhibition of repaglinide metabolism in HLM 
was observed by quercetin (CYP2C8 inhibitor) and by itraconazole (CYP3A4 
inhibitor), supporting the conclusion that CYP2C8 and CYP3A4 are about equally 
important in the in vitro biotransformation of repaglinide.    
Fenofibrate, bezafibrate and gemfibrozil all moderately inhibited CYP2C8 and 
repaglinide metabolism in vitro, but had no effect on CYP3A4. These similarities 
in their in vitro inhibitory characteristics do not correlate with the observed 
differences in their in vivo interaction potential, and suggest that inhibition of 
CYP2C8 by parent gemfibrozil does not explain its drastic interaction with 
repaglinide in vivo.9   
A significant competitive inhibition of CYP3A4, CYP2C8 and repaglinide 
metabolism by rifampicin was found in vitro. The average rifampicin Cmax after a 
dose of 600 mg corresponds to approximately 40% and 60% of our Ki values for 
CYP2C8 and CYP3A4, respectively. Rifampicin has also been reported to inhibit 
transporters, e.g. OATP1B1 and OATP1B3. The unbound fraction of rifampicin is 
about 30%, and during the absorption phase its concentration in the portal blood 
and liver is assumably higher than in peripheral plasma. Thus, if a significant 
amount of rifampicin is in the blood and liver, it can blunt its own observed 
inducing effect on a CYP2C8 and CYP3A4 substrate, such as repaglinide. 
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2 In vivo studies 
The plasma concentrations of repaglinide were significantly increased by 
trimethoprim (repaglinide AUC +61%), cyclosporine (+144%), and telithromycin 
(+77%), while bezafibrate, fenofibrate, montelukast, or pioglitazone did not 
affect repaglinide pharmacokinetics (Figure 6, Table X). The findings from 
studies II-VI are presented in more detail in the following sections. 





















































































Table X. Effects of studied drugs on the blood glucose response to repaglinide (0.25mg 
single oral dose), compared to the respective placebo phases.          
Mean difference in blood glucose concentration variables compared to the 







concentration   
0 to 3 h 
Mean 
concentration   
0 to 7 h 
Mean 
concentration   
0 to 12 h 
Bezafibrate (II) 0.2 0.0 0.1 0.0 - 
Fenofibrate (II) 0.1 0.3 0.2 0.1 - 
Trimethoprim (III) -0.1 -0.3 -0.1 -0.1 - 
Cyclosporine (IV) -0.1 -0.1 0.0 0.0 0.0 
Telithromycin (V) -0.4 -0.7 * -0.6 * -0.4 -0.2 




-0.4 -0.5 * -0.4 -0.3 -0.2 
Pioglitazone (VI) 0.0 -0.3 0.0 0.0 0.1 
* P < .05 versus the placebo phase. 
2.1 Effects of bezafibrate and fenofibrate (II) 
Bezafibrate and fenofibrate had no statistically significant effects on any of the 
pharmacokinetic variables of repaglinide. In the bezafibrate and fenofibrate 
phases, the mean AUC0-∞ for repaglinide was 99.1% and 99.4% of the 
corresponding value during the placebo phase, respectively. The t½ of 
repaglinide was 1.3 h in all phases.  
The AUC0-8 values of bezafibrate and fenofibrate were 18.1 ± 6.3 mg·L/h and 
52.8 ± 21.7 mg·L/h, respectively, and Cmax values were 4.9 ± 1.4 mg/L and 8.0 
± 3.1 mg/L, respectively. 
Bezafibrate and fenofibrate did not change the effect of repaglinide on the blood 
glucose concentrations, when compared with placebo. None of the subjects had 
symptomatic hypoglycaemia. 
2.2 Effect of trimethoprim (III) 
The plasma concentrations of repaglinide were increased by trimethoprim 
compared with placebo. Trimethoprim raised the AUC0-∞ and Cmax of repaglinide 
by 61% (P < .001) and 41% (P < .001), respectively, and prolonged the t½ of 
repaglinide from 0.9 to 1.1 h (P = .001). Trimethoprim had no effect on the 
pharmacokinetics of the M1 metabolite of repaglinide, but decreased the 
M1:repaglinide AUC ratio by 38% (P < .001).  
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The AUC0-8 and Cmax of trimethoprim were 18.7 ± 3.8 mg·L/h and 2.9 ± 0.6 
mg/L, respectively. There was a correlation between the AUC0-8 of trimethoprim 
and the increase in the AUC of repaglinide caused by trimethoprim (Pearson r = 
0.68, P = .04).  
No significant differences were seen in the blood glucose response between the 
placebo and trimethoprim phases. None of the subjects had symptomatic 
hypoglycaemia. 
2.3 Effect of cyclosporine (IV) 
The plasma concentrations of repaglinide were significantly raised by 
cyclosporine. Cyclosporine raised the mean Cmax and AUC0-∞ of repaglinide to 
175% (P = .003) and 244% (P < .001) of control values, respectively. There 
was no statistically significant change in the tmax or t½ of repaglinide.  
Compared with the corresponding control values, cyclosporine significantly 
increased the urinary excretion of unchanged repaglinide (to 265%) and its 
metabolites M2 (to 748%) and M4 (to 499%) but had no significant effect on the 
excretion of M1. However, cyclosporine significantly reduced the ratio of M1 to 
repaglinide (by 62%) and increased the ratio of M2 to repaglinide (to 258%) and 
M4 to repaglinide (to 181%) in urine. The renal clearance of repaglinide 
remained unchanged by cyclosporine. 
The mean Cmax and AUC0-∞ and median tmax values of cyclosporine were 664 ± 
158 ng/mL, 1998 ± 636 ng/mL, and 80 min, respectively. There was a 
correlation between the AUC0-∞ of cyclosporine and the increase in the AUC0-∞ of 
repaglinide caused by cyclosporine (Pearson r = 0.61, P = .034).  
In subjects with the SLCO1B1 521TC genotype, the increase in the AUC0-∞ of 
repaglinide by cyclosporine was 42% smaller than in subjects with the 521TT 
(reference) genotype (P = .047). No other statistically significant associations 
between the investigated SNPs or haplotypes and the extent of interaction or 
repaglinide baseline pharmacokinetics were found.  
Although no statistically significant differences were observed in the mean blood 
glucose response between the placebo and cyclosporine phases, the blood 
glucose response of individual subjects correlated with the degree of 
pharmacokinetic interaction between cyclosporine and repaglinide. However, 
none of the subjects had symptomatic hypoglycaemia. The ratio of repaglinide 
Cmax values between the phases correlated with the difference in the mean blood 
glucose change from 0 to 3 h (P = .045) and with the difference in maximum 
blood glucose increase (P = .031). The ratio of repaglinide AUC0-∞ values 
between the phases correlated with the difference in the mean blood glucose 
change from 0 to 3 hours (P = .038). The subject with the greatest (5-fold) 
increase in repaglinide AUC0-∞ also had the greatest enhancement of the blood 
glucose–lowering effect of repaglinide.  
2.4 Effects of telithromycin and montelukast (V) 
2.4.1 Effect of telithromycin 
Telithromycin considerably increased the plasma concentrations and urinary 
excretion of unchanged repaglinide but did not affect its t½. Repaglinide mean 




Cmax and AUC0-∞ were raised to 138% (P = .006) and 177% (P < .001) of the 
placebo values, respectively.  
Telithromycin decreased the Cmax and AUC0-∞ of the metabolite M1 but increased 
those of metabolites M2 and M4. The M1:repaglinide AUC0-∞ ratio was lowered 
by 68% (P < .001), and the M2:repaglinide and M4:repaglinide AUC0-∞ ratios 
were raised to 125% (P = .012) and to 153% (P < .001) by telithromycin, 
respectively. Telithromycin increased the urinary excretion of unchanged 
repaglinide to 229% (P < .001), and its metabolites M2 to 180% (P < .001) and 
M4 to 198% (P < .001), but reduced the excretion of M1 by 41% (P < .001) 
compared to placebo. Telithromycin also reduced M1:repaglinide ratio in urine by 
80% (P = .001), compared to placebo. 
The Cmax and AUC0-13 of telithromycin were 1180 ± 250 ng/mL and 5350 ± 1520 
ng·h/mL, respectively, in the telithromycin phase. There were no significant 
correlations between the pharmacokinetic variables of telithromycin and the 
extent of interaction between telithromycin and repaglinide. 
Compared with the placebo phase, the maximum (by 0.7 mmol/L, P = .002) and 
mean (0 to 3 h) blood glucose concentrations (by 0.5 mmol/L, P = .008) were 
reduced in the telithromycin phase. None of the subjects had symptomatic 
hypoglycaemia. 
2.4.2 Effect of montelukast 
Montelukast had no statistically significant effect on any of the pharmacokinetic 
variables of parent repaglinide or its metabolites M1, M2 or M4, compared to the 
placebo phase. Repaglinide Cmax and AUC0-∞ values during the montelukast 
phase were 92% and 99% of those during the placebo phase. 
No significant differences were observed in the blood glucose concentrations 
between the placebo and montelukast phases. None of the subjects had 
symptomatic hypoglycaemia. 
2.4.3 Effect of telithromycin and montelukast 
The combination of telithromycin and montelukast raised the mean Cmax and 
AUC0-∞ of repaglinide to 146% (P = .002) and 188% (P < .001) of placebo 
values, respectively. There were no significant differences in any of the 
pharmacokinetic variables of repaglinide between the combination phase and the 
telithromycin phase.  
The combination decreased the Cmax and AUC0-∞ of the M1 but increased those of 
the M2 and M4, when compared to the placebo phase. The combination lowered 
the M1:repaglinide AUC0-∞ ratio by 73%, and raised the M2 and M4 to 
repaglinide AUC0-∞ ratios to 118% and to 141%, respectively, when compared to 
the placebo phase. The combination increased also the urinary excretion of 
unchanged repaglinide to 235% (P < .001), and its metabolites M2 to 186% (P 
= .001), and M4 to 191% (P < .001), but reduced the excretion of M1 by 44% 
(P < .001). The combination decreased the M1:repaglinide, M2:repaglinide, and 
M4:repaglinide ratios in urine when compared to placebo.  
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Montelukast had no significant effect on the pharmacokinetics of telithromycin, 
and telithromycin had no significant effect on the pharmacokinetics of 
montelukast.  
The maximum blood glucose concentration was reduced in the combination 
phase compared to the placebo phase by 0.5 mmol/L (P = .030). None of the 
subjects had symptomatic hypoglycaemia. 
2.5 Effect of pioglitazone (VI) 
In the pioglitazone phase, the Cmax and AUC0-∞ of repaglinide were 100% (P = 
.99) and 90% (P = .22) of the control values, respectively. The t½ was 
unchanged, about 1.0 h in both phases. The median tmax of repaglinide was 40 
min and 20 min in the placebo and pioglitazone phases, respectively (P = .014). 
On the study day, pioglitazone mean Cmax and AUC0-13 of pioglitazone were 778 
± 186 ng/mL and 5090 ± 1320 ng·h/mL, respectively. 
The 5-day pioglitazone administration did not change the baseline blood glucose 
concentrations (4.6 ± 0.4 mmol/l), compared to the placebo phase (4.5 ± 0.2 
mmol/l). Neither the minimum, maximum, nor the mean change of blood 
glucose after repaglinide intake were changed statistically significantly by 
pioglitazone. None of the subjects had symptomatic hypoglycaemia. 
2.6 Discussion 
2.6.1 Effect of bezafibrate, fenofibrate, montelukast, and pioglitazone 
Administration of the usual therapeutic doses of bezafibrate, fenofibrate, 
montelukast, and pioglitazone had no significant effect on the pharmacokinetics 
or pharmacodynamics of repaglinide in healthy subjects. The AUC and Cmax 
values for  bezafibrate, fenofibrate, montelukast, and pioglitazone, as well as 
their interindividual variation, were comparable with those found in previous 
studies,18,178,180,183,212,213 and based on individual plasma concentrations, 
compliance to pre-treatment medication was good, indicating that the lack of 
interaction was not caused by a failure to take the drugs.  
The lack of interaction between bezafibrate or fenofibrate with repaglinide is  
clearly in contrast to the potent effect of gemfibrozil on the pharmacokinetics of 
repaglinide; gemfibrozil has increased repaglinide AUC 8.1-fold, greatly 
enhancing its glucose-lowering effects and prolonging its t½.9 Bezafibrate and 
fenofibrate inhibited CYP2C8 and repaglinide metabolism in vitro similarly as 
parent gemfibrozil,9 but the characteristics of gemfibrozil glucuronide 
conjugate214,215 probably explain the differences in the interaction potential of 
these three fibrates in vivo. In vivo, gemfibrozil is a potent inhibitor of CYP2C8 
and it has increased the AUC of several CYP2C8 substrates (e.g. cerivastatin,13 
rosiglitazone,216 and pioglitazone).202 It was recently demonstrated that 
gemfibrozil 1-0-ß-glucuronide is a potent and selective metabolism-dependent 
CYP2C8 inhibitor, and also inhibitor of OATP1B1.214,215 Bezafibrate and 
fenofibrate appear not to be sufficiently potent CYP2C8 (or OATP1B1) inhibitors 
to influence repaglinide metabolism in vivo, especially as their available 
concentration to inhibit the enzyme is low due to high plasma protein binding 
(bezafibrate 95%, fenofibrate 99%).178   




Montelukast is a very potent and selective CYP2C8 inhibitor in vitro (Ki 0.0092 
µM),16 and based on in vitro CYP2C8 inhibition data and therapeutic montelukast 
plasma concentrations, it has been estimated that montelukast would increase in 
the AUC of a CYP2C8-cleared drug from 2-fold (using unbound montelukast Cmax, 
assuming a 1% free fraction) to over 100-fold (based on total montelukast 
Cmax).16 The available in vivo and in vitro evidence suggests that the contribution 
of CYP2C8 to the metabolic clearance of repaglinide is at least 50%, and it is 
likely that during the phases of study V that included inhibition of CYP3A4 by 
telithromycin, the contribution of CYP2C8 was even higher. However, even with 
concomitant CYP3A4 inhibition, repaglinide pharmacokinetics and the ratio of M4 
(formed almost exclusively by CYP2C8 in vitro)7 to repaglinide in plasma and in 
urine were unaffected by montelukast. Accordingly, the lack of effect of 
montelukast on repaglinide pharmacokinetics and CYP2C8-mediated metabolism 
suggests that the effect of montelukast on CYP2C8 in vivo is very weak.  
The apparent discrepancy between the previously published estimates and our 
findings could be explained by underestimation of montelukast protein binding. 
The plasma protein binding of montelukast has been reported to be more than 
99%, but the exact free fraction is not known.213,217,218 Assuming a free fraction 
of 1% for montelukast and that only 50% of the metabolism of repaglinide is 
mediated by CYP2C8, the estimated increase in the AUC of repaglinide by 
montelukast would yield 30%. However, an assumed free fraction of 0.1%, 
montelukast would be estimated to cause only a 4-10% increase in the AUC of a 
drug cleared 50-100% by CYP2C8. The latter estimates agree well with our in 
vivo results and suggest that the high protein binding of montelukast limits its 
concentration available to CYP2C8 in vivo.  
The efficacy of pioglitazone-repaglinide combination therapy has been compared 
to monotherapy with pioglitazone or repaglinide in patients with type 2 
diabetes.20 In this 24-week parallel-group study with 246 adult patients 
(baseline HbA1c about 9%), the effect of the combination on glycemic parameters 
was much better (mean change in HbA1c -1.8%) than that of either repaglinide 
(HbA1c -0.2%) or pioglitazone (HbA1c +0.3%) alone, but the plasma 
concentrations of pioglitazone and repaglinide were not determined in that 
study. Pioglitazone is a relatively potent in vitro inhibitor of CYP2C8 (Ki 1.7 µM) 
and CYP3A4 (Ki 11.8 µM),19 and study VI was designed to test the hypothesis 
that inhibition of repaglinide metabolism by pioglitazone contributes to the 
observed pharmacodynamic efficacy their combination therapy.  
Using the Ki  for CYP2C8 and estimated total portal Cmax,16 pioglitazone is 
estimated to cause an almost 3-fold increase in the AUC of a drug cleared solely 
by CYP2C8, and about 1.5-fold increase in the AUC of a drug of which 50% is 
metabolised by CYP2C8 (such as repaglinide). However, the high plasma protein 
binding (97-99%)200 of pioglitazone probably limits its intracellular concentration 
available to the enzyme in vivo, and calculations based on the free plasma 
concentrations of pioglitazone estimate practically no increase in repaglinide 
AUC, which agrees well with the observed in vivo results. These results strongly 
suggest that pioglitazone does not inhibit repaglinide metabolism in vivo, and 
that its inhibitory effect on CYP2C8 and CYP3A4 is very weak in humans. The 
synergistic effect of pioglitazone-repaglinide combination therapy in patients with 
type 2 diabetes can be explained by a slowly developing pharmacodynamic 
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interaction without a pharmacokinetic component. Repaglinide reduces blood 
glucose concentrations by enhancing short-term insulin release,2 whereas the 
effects of pioglitazone are seen more slowly, mediated via activation of the 
nuclear receptor PPAR-γ.219  
2.6.2 Effect of trimethoprim, cyclosporine, and telithromycin  
Therapeutic doses of trimethoprim and telithromycin used in the treatment of 
acute infections, and cyclosporine at doses used e.g. in the treatment of 
rheumatoid arthritis were found to significantly increase repaglinide plasma 
concentrations. 
Trimethoprim elevated the plasma concentrations of repaglinide, prolonged its 
half-life, and decreased the M1:repaglinide AUC ratio, indicating that it had 
inhibited the metabolism of repaglinide to M1 (formed by both CYP2C8 and 
CYP3A4 in vitro).7 Trimethoprim, a selective and moderately potent CYP2C8 
inhibitor,17 also inhibited the metabolism of repaglinide in vitro in HLM. 
Itraconazole, which inhibits CYP3A4207 much more potently  than trimethoprim 
inhibits CYP2C8 according to Ki values, has had a smaller effect on the AUC of 
repaglinide in vivo (a 40% increase),9 suggesting that the contribution of 
CYP2C8 in the biotransformation of repaglinide in vivo is important. 
Trimethoprim had no significant effect on the blood glucose-lowering effect of 
repaglinide in this low-dose study, but concomitant use of trimethoprim may 
increase the blood glucose-lowering effect of repaglinide and the risk of 
hypoglycamia, particularly if higher repaglinide doses are used. 
Even short-term use of cyclosporine markedly increased the plasma 
concentrations of repaglinide. There was large variation in the extent of the 
interaction, the increase in repaglinide AUC ranged from 1.2-fold to over 5-fold 
even in this homogeneous group of young healthy volunteers, partly explained 
by genetic factors and variability in cyclosporine concentrations. The greatest 
increases in the plasma repaglinide concentrations were associated with the 
greatest increases in the blood glucose–lowering effect of repaglinide. There was 
also a correlation between cyclosporine AUC and the increase in repaglinide AUC 
by cyclosporine.  
It has been reported, that cyclosporine moderately inhibits CYP3A4,220 but has 
no significant effect on CYP2C8.102 In addition, our in vitro results demonstrated 
that cyclosporine inhibited the mainly CYP3A4-mediated repaglinide metabolism 
(to M1 and M2), without an effect on M4 formed by mainly CYP2C8. The ratio of 
M1 to repaglinide in urine was significantly decreased by cyclosporine, 
suggesting that cyclosporine inhibited the formation of also M1 in vivo, similarly 
as in vitro. On the other hand, the ratios of M2 to repaglinide and M4 to 
repaglinide in urine were increased, suggesting that cyclosporine did not inhibit 
the formation of these major metabolites in vivo, but may have inhibited their 
hepatic (or biliary) elimination. Cyclosporine has been shown to inhibit efflux 
transporters (P-glycoprotein, MRP),221,222 expressed in the canalicular membrane 
of the hepatocyte.  
Cyclosporine is also a potent inhibitor of OATP1B1,22 and the pharmacokinetics of 
repaglinide depend on the SLCO1B1 (encoding OATP1B1) genotype.164 The effect 
of cyclosporine on repaglinide pharmacokinetics was smaller in carriers of 
SLCO1B1 521T>C SNP than in noncarriers (wild type). Furthermore, cyclosporine 




reduced the M1:repaglinide AUC ratio less than itraconazole,9 even though it 
increased repaglinide AUC much more than itraconazole or clarithromycin.8,9 
Inhibition of CYP3A4-mediated biotransformation of repaglinide by cyclosporine 
is unlikely to solely explain their interaction because stronger CYP3A4-inhibitors 
have had a smaller effect on repaglinide AUC, and because M1 only a minor 
repaglinide metabolite in vivo. Thus, inhibition of the OATP1B1-mediated hepatic 
uptake of repaglinide by cyclosporine probably contributes to their interaction.  
Telithromycin significantly increased the plasma concentrations and effects of 
repaglinide. The M1:repaglinide ratio in plasma and urine was decreased by 
telithromycin, indicating that telithromycin inhibited CYP3A4-catalysed 
biotransformation of repaglinide to M1. The increase in repaglinide AUC by 
telithromycin was greater than the increases previously caused by other potent 
inhibitors of CYP3A4 (itraconazole, clarithromycin).8,9 Telithromycin is a 
competitive inhibitor of CYP3A4 in vitro, and has considerably increased the AUC 
of CYP3A4 substrates simvastatin (9-fold) and midazolam (6-fold).18 In plasma, 
the AUC ratios of M2 and M4 to repaglinide were increased by telithromycin, but 
there was a slight (nonsignificant) decrease in the ratios of M2 and M4 to 
repaglinide in urine. These findings may be explained by increased renal 
clearance of repaglinide caused by telithromycin. The Cmax and AUC of 
repaglinide were increased by telithromycin, while no effect on t½ was seen. The 
formation of the M1 metabolite (formed primarily by CYP3A4 in vitro) was 
inhibited already before the Cmax of repaglinide was reached. These findings 
suggest that telithromycin raised the plasma concentrations of repaglinide by 
inhibiting its presystemic CYP3A4-mediated metabolism, occurring presumably in 
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G E N E R A L   D I S C U S S I O N 
1 Methodological consideration 
1.1 In vitro studies 
HLM and rhCYPs are widely used and reliable systems for drug-drug interaction 
and drug metabolism studies.83 In studies I and III, the aim was to study the 
total elimination of repaglinide by HLM (and inhibition of its elimination), rather 
than analysing the formation rates of specific repaglinide metabolites. Therefore, 
a substrate depletion method was used,223 and calculations were based on the 
rate of disappearance of parent repaglinide in incubations. When using this 
method in HLM for a substrate that is metabolised by more then one enzyme, 
the determined apparent kinetic constants reflect the sum of several enzymatic 
reactions. Kinetic constants determined this way are less accurate than those 
determined for a single enzymatic pathway, using e.g. rhCYPs.137  
To avoid interindividual variation, pooled HLM were used in the studies instead of 
HLM from individual donors. Pooled HLM adequately represent the population 
average (Caucasian), and contain all the enzymes present in the endoplasmic 
reticulum of hepatocytes, with their relative abundances conserved. Using the 
HLM system, the contributions of different enzymes to the metabolism of a 
substrate can be determined using selective inhibitors, and possible metabolism-
dependent inhibition can be assessed using preincubations.224 However, 
conjugative processes such as glucuronidation are more difficult to study in HLM, 
because the active site of UGTs are inside the lumen of endoplasmic reticulum in 
the cell and inside the microsomal micelle in HLM. The study of drug 
glucuronidation in HLM requires disruption of the microsomal membrane e.g. 
using detergents or pore-forming antifungal agent alamethicin.225   
Studies in HLM were complemented by use of rhCYP2C8 and rhCYP3A4 to 
characterise their roles in repaglinide elimination (I), and in the formation of 
repaglinide metabolites M1, M2, and M4 (IV). The activity of one enzyme can be 
directly determined in the rhCYP system, and the formation rates of repaglinide 
metabolites by rhCYP2C8 and rhCYP3A4 could be directly compared. However, 
scaling factors are needed to compare results from rhCYPs to those obtained in 
HLM or to make in vivo predictions, and no consensus has been reached 
concerning different scaling approaches.147    
Organic solvents are needed in in vitro drug metabolism studies, because most 
drugs are so poorly soluble in water. Excess of organic solvents inhibits CYP-
mediated biotransformation, and the susceptibility of individual CYPs to such 
inhibition differs greatly.138 In our studies the drugs were dissolved in methanol, 
and a final concentration of 1% (v/v) was used. Methanol and acetonitrile have 
been reported to be the most suitable for in vitro CYP studies, and 1% methanol 
concentration alters the activity of CYP2C8 and CYP3A4 by <8%.138   
The choice of substrate concentrations used in in vitro studies is critical, 
especially if only a single substrate concentration is used. The contribution of 
different CYP isoforms to the metabolism of a substrate can differ greatly at 
different substrate concentrations.6 When studying probe substrate reactions in 




HLM, the substrate concentration was near the Km of the substrate. When 
determining the Ki value a range of substrate concentrations below and above 
the Km were used.  
The peak concentration of repaglinide after the highest recommended single 
dose of 4 mg is approximately 0.22 µM.2 Repaglinide is rapidly eliminated from 
the body, and in vivo, repaglinide concentrations are therefore typically <0.2 µM. 
Only about 2% of repaglinide in plasma is unbound,161 and the concentration 
available for metabolism by CYP enzymes is probably <0.02 µM. The limit of 
quantification method available (at low concentrations) and drug solubility (at 
higher concentrations) restrict the choice of substrate concentration. The range 
of repaglinide concentrations used to study the effects of other drugs on 
repaglinide metabolism and the formation of repaglinide metabolites was 0.2-2 
µM, in order to reliably quantify the metabolism of repaglinide and formation of 
its metabolites, and inhibition of these processes. 
These in vitro studies could have been improved by studying the effect of 
gemfibrozil glucuronide on repaglinide metabolism by HLM and rhCYPs. Attempts 
were made to determine the effect of gemfibrozil glucuronide on CYP2C8 activity 
in study I using preincubation in the presence of glucuronic acid and alamethicin, 
but variation between duplicated was large in these multi-step in vitro assays. In 
addition, in vitro studies determining the capacity of different transporters to 
carry repaglinide (and effect of possible inhibition to such processes) are lacking.  
1.2 In vivo studies 
A randomised, balanced cross-over design was used in the in vivo studies with 
healthy volunteers. In this design, the subjects serve as their own controls, 
limiting the effects of interindividual variation. The elimination half-lives of the 
pretreatment drugs and their metabolites have been reported to be no more 
than 24 h, and the 2 or 4 week wash-out period between the phases was 
sufficient to minimise possible carry-over effects. Compared with the fasted 
state, coadministration of food has only minor effects on the pharmacokinetic 
parameters of repaglinide.2 Furthermore in our studies, the food intake was 
standardised and strictly controlled to minimise the possible effect of food 
ingestion on the pharmacokinetics of repaglinide. 
For safety reasons, only a small, 0.25 mg dose of repaglinide was used in the 
studies in healthy volunteers and carbohydrate intake was frequent to avoid 
hypoglycaemia. Healthy subjects are more sensitive to the pharmacodynamic 
effects of repaglinide than diabetic patients, because insulin secretion capacity is 
decreased in diabetics.226 The possibility of a significant inhibitory interaction, 
resulting in increased concentrations and effects of repaglinide, was taken into 
consideration when selecting the dose. The pharmacokinetics of repaglinide are 
linear with respect to dose, and the presence of type 2 DM has not been 
associated with altered repaglinide pharmacokinetics compared to healthy 
volunteers.1 Thus, it is reasonable to assume that the findings from studies with 
a 0.25 mg repaglinide dose can be extrapolated to normal therapeutic doses 
(0.5–4 mg) of the drug in diabetic patients.  
The relatively modest (or absent) differences in the blood glucose-lowering effect 
of repaglinide despite increased plasma concentrations in the in vivo studies 
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could be explained, at least partially, by the repeated intake of food as well as by 
the use of a subtherapeutic dose of repaglinide. The enhancement of insulin 
secretion and reduction in postprandial hyperglycaemia by repaglinide (0.5-4 
mg) have been reported to be dose-dependent.1 Thus, while increases in 
repaglinide AUC have not caused hypoglycaemic episodes under the 
experimental conditions, similar increases in the AUC of therapeutic repaglinide 
doses may be associated with enhanced blood-glucose lowering effect of 
repaglinide and increased risk of hypoglycaemia.  
The timing of repaglinide administration (1 h after the last pretreatment dose) 
was chosen to ensure the adequate absorption of pretreatment drugs before 
repaglinide ingestion. The compliance to pretreatment drug therapy was ensured 
by measuring their concentrations on the study days, and by adhering to 
pretreatment schedule (each dose marked taken by the subjects).  
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2 Pharmacokinetic drug-drug interactions of repaglinide 
2.1 Role of CYP enzymes in repaglinide metabolism  
Repaglinide is almost completely eliminated by metabolism and >90% of the 
dose is excreted into faeces.5 The major metabolites of repaglinide formed in 
vivo are metabolite M1 (about 4% of the dose) and metabolite M2 (about 66%).5 
Of the CYP enzymes investigated in vitro, only CYP2C8 and CYP3A4 have been 
shown to contribute to the metabolism of repaglinide to any significant extent.7 
Metabolism of repaglinide to M1 and M2 is catalysed by both CYP2C8 and 
CYP3A4, and CYP3A4 has been reported to be the principal enzyme responsible 
for these reactions in vitro.7  
However, the total plasma concentrations of repaglinide in vivo are much lower 
than the concentrations used in the above-mentioned in vitro study,2 and the 
relative contribution of CYP3A4 to repaglinide metabolism may have been 
overestimated, compared to the in vivo situation. Our in vitro results showed 
that at higher repaglinide concentrations (>2 µM), the contribution of CYP3A4 
became greater than that of CYP2C8, but the reaction velocities of repaglinide 
metabolism by rhCYP2C8 and rhCYP3A4 were approximately equal at lower 
repaglinide concentrations in vitro. In addition, the in vitro CLint values of 
rhCYP2C8 and rhCYP3A4 for repaglinide metabolism were similar, and chemical 
inhibition of CYP2C8 and CYP3A4 resulted in a similar reduction of total 
repaglinide metabolism.  
In pharmacokinetic studies, the M1:repaglinide AUC ratio has been decreased by 
trimethoprim (CYP2C8 inhibitor), by telithromycin (CYP3A4 inhibitor), and by 
itraconazole (CYP3A4 inhibitor).9 Telithromycin and cyclosporine also decreased 
the M1:repaglinide ration in urine. These findings indicate that both CYP2C8 and 
CYP3A4 contribute to biotransformation of repaglinide to M1 in vivo.  
The M2:repaglinide AUC ratio was increased by telithromycin, and cyclosporine 
increased M2:repaglinide ratio in urine. There was a slight (nonsignificant) 
decrease in the ratio of M2 to repaglinide in urine by telithromycin, probably 
explained by the increased renal clearance of repaglinide in the telithromycin 
phase. These findings suggest that inhibition of CYP3A4 does not affect the 
biotransformation of repaglinide to its main metabolite M2 in vivo. It has been 
hypothesised that the biotransformation of repaglinide to M2 would require two 
enzymatic steps, i.e. opening of the piperadine ring and formation of dicarboxylic 
acid. Though CYP3A4 is more important than CYP2C8 in the formation of M2 in 
vitro, it appears that CYP2C8 (or possibly other enzymes) mainly catalyses its 
formation in vivo.  
Telithromycin has increased the M4:repaglinide AUC ratio, and cyclosporine has 
increased M4:repaglinide ratio in urine. There was a slight (nonsignificant) 
decrease in the M4:repaglinide in urine by telithromycin, but the increased renal 
clearance of repaglinide in the telithromycin phase probably explains this finding. 
These findings suggest that CYP3A4 plays only a minor role in the 
biotransformation of repaglinide to M4 in vivo, similarly as in vitro.7  
The drastic gemfibrozil-repaglinide in vivo interaction9 does not involve the 
inhibition of CYP3A4, but probably results from simultaneous inhibition of 
CYP2C8 and OATP1B1. Furthermore, the effect potent CYP3A4 inhibitors on 
GENERAL DISCUSSION: Pharmacokinetic drug-drug interactions of repaglinide 
  68
repaglinide AUC has been smaller than (clarithromycin and itraconazole),8,9 or 
similar to (telithromycin) the effect of trimethoprim, a selective but only 
moderately potent CYP2C8 inhibitor.17 In addition, CYP2C8 genotype has been 
shown to correlate with repaglinide AUC.165  
Altogether, these findings suggest that the contribution of CYP2C8 to the 
metabolism of repaglinide is at least as important as that of CYP3A4 in vivo. 
Similarly, the contributions of the two enzymes to the metabolism of repaglinide 
in vitro appear to be about equally important, if the repaglinide concentration 
used is not too high.  
2.2 Role of OATP1B1 in repaglinide pharmacokinetics  
In a recent publication that combined the results from several pharmacokinetic 
studies, the AUC of repaglinide was 3-fold higher in subjects homozygous for the 
functionally significant SLCO1B1 c.521T>C SNP (n=4), and 41% higher in 
heterozygous subjects (n=16), compared with subjects with the reference 
genotype (n=36), suggesting a major role for hepatic uptake transporter 
OATP1B1 in repaglinide pharmacokinetics.164 In addition, the effect of 
cyclosporine on repaglinide AUC was smaller in those subjects with the SLCO1B1 
c.521T>C SNP compared to those with the wild-type SLCO1B1 genotype, and 
the observed interaction was probably caused by inhibition of both CYP3A4 and 
OATP1B1.  
Although these genetic association findings strongly suggest that repaglinide is a 
substrate for OATP1B1, there is no direct evidence (e.g. in vitro studies) about 
the capability of OATP1B1 to transport repaglinide. However, repaglinide has 
been shown to have high affinity for OATP1B1 in vitro, and repaglinide has 
inhibited OATP1B1 activity in transfected MDCKII cells recombinantly expressing 
OATP1B1.227  
2.3 Pharmacokinetic studies with repaglinide 
In studies in healthy volunteers, CYP2C8 or CYP3A4 inhibitors without an 
additional mechanism of interaction have caused <80% increases in repaglinide 
AUC (Table XI).8,9,12 Cyclosporine and gemfibrozil9 have caused the greatest 
increases in repaglinide AUC (2.4-fold and 8.1-fold, respectively), probably by 
inhibiting both CYP-mediated biotransformation and OATP1B1-mediated hepatic 
uptake of repaglinide.  
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Table XI. The effect of CYP or transporter inhibitors on the pharmacokinetics of 
repaglinide. Results are presented as mean changes compared to placebo (% of control) 
with the proposed mechanism of investigated interaction.  
Repaglinide 
pharmacokinetic variables   
(% of control) 
Metabolite to repaglinide 
ratios (% of control)             
Drug studied with 
repaglinide 




Clarithromycin8  168%* 140%* 121%* - - - 
Itraconazole9  148%* 141%* 123% 21% - - 
Ketoconazole12 † 107% 115% 100% - - - 
Telithromycin (V) 138%* 177%* 86% 32%* 125%* 153%* 
CYP3A4 
Trimethoprim (III) 141%* 161%* 120%* 62%* - - 
Bezafibrate (II) 107% 99% 100% - - - 
Fenofibrate (II) 118% 99% 100% - - - 
Montelukast (V) 92% 99% 100% 96% 104% 109% 
CYP2C8 
Pioglitazone (VI) 100% 90% 95% - - - 
CYP2C8 and 
CYP3A4 
Gemfibrozil9  239%* 808%* 285%* 93% - - 
CYP2C8 and 
OATP1B1 










146%* 188%* 87% 27%* 118%* 141%* 
CYP2C8 and 
CYP3A4 
* P < .05 versus the placebo phase.  
† Repaglinide dose 2 mg, in other studies 0.25 mg.   
# Metabolite ratios determined from amounts excreted in urine, other metabolite ratios are AUC 
ratios. 
 
2.3.1 Effect of CYP3A4 inhibition  
In vivo, CYP3A4 inhibitors clarithromycin,8 itraconazole,9 ketoconazole,12 and 
telithromycin have all been shown to increase the plasma concentrations of 
repaglinide (Table XI). In vitro, the CYP3A4 Ki values determined for itraconazole 
have ranged from 15 nM to 11 µM, but the metabolites of itraconazole also 
contribute to the inhibitory effects of itraconazole.207 Ketoconazole inhibits 
CYP3A4 with an estimated Ki of 0.02-0.11 µM,102  and clarithromycin is a 
mechanism-based inhibitor of CYP3A4.228 Telithromycin is a competitive inhibitor 
of CYP3A4, and it has increased the AUC of CYP3A4 substrates (e.g. midazolam 
6-fold).18 Telithromycin has inhibited the biliary excretion of the P-glycoprotein 
and MRP2 substrate doxorubicin in rats, but its effect on OATP1B1 has not been 
studied.229 Because these potent CYP3A4-inhibitors have considerably increased 
repaglinide AUC (by 15-77%), with only moderate (or absent) effects on its t½, it 
is likely that they have mainly inhibited the CYP3A4-mediated repaglinide 
biotransformation during the first-pass. For example, itraconazole9 and 
telithromycin both inhibited the formation of M1 already before repaglinide Cmax 
was reached, indicating inhibition of first-pass metabolism.  
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Grapefruit juice has been shown to inhibit the activity and decrease the content 
of intestinal CYP3A4, and increase the plasma concentrations of orally 
administered CYP3A4 substrates (e.g. midazolam and simvastatin).230 Grapefruit 
juice has caused a 13% increase in repaglinide geometric mean AUC suggesting 
that grapefruit juice inhibited the CYP3A4-mediated presystemic metabolism of 
repaglinide in the intestine.165  
Though both CYP2C8 and CYP3A4 are functionally expressed in the intestinal 
mucosa, the intestinal CYP3A4 content exceeds that of CYP2C8, and CYP2C8 is 
likely to play only a minor role in intestinal drug metabolism.89 Thus, during the 
first-pass metabolism of repaglinide, the contribution of CYP3A4 may be higher 
than that of CYP2C8. 
2.3.2 Effect of CYP2C8 inhibition  
Trimethoprim, a selective CYP2C8 inhibitor, inhibited repaglinide metabolism in 
vitro, and increased repaglinide AUC, prolonged its t½, and decreased the 
M1:repaglinide AUC ratio in vivo. Gemfibrozil has increased repaglinide AUC 8.1-
fold, greatly enhancing its glucose-lowering effects and prolonging its t½.9 In 
vivo, gemfibrozil is a potent inhibitor of CYP2C8 and it has increased the AUC of 
several CYP2C8 substrates (e.g. cerivastatin,13 and rosiglitazone216). It was 
recently demonstrated that gemfibrozil 1-0-ß-glucuronide is a potent and 
selective metabolism-dependent CYP2C8 inhibitor.214,215  
These findings suggest that trimethoprim and gemfibrozil (and its glucuronide 
conjugate) increased repaglinide plasma concentrations by inhibiting its CYP2C8-
mediated metabolism, but inhibition of OATP1B1 by gemfibrozil probably 
significantly contributes to their interaction. The effect of these CYP2C8 inhibitors 
on repaglinide t½ has been greater than the effect of CYP3A4 inhibitors,8,9,12 
indicating that in the hepatic clearance of repaglinide  the contribution of CYP2C8 
may be greater than that of CYP3A4. 
2.3.3 Effect of gemfibrozil and cyclosporine  
Cyclosporine (and its metabolites) inhibits CYP3A4, P-glycoprotein, and 
OATP1B122-24,188 whereas gemfibrozil (and its glucuronide conjugate) inhibits 
CYP2C8 and OATP1B1.214,215 Both cyclosporine and gemfibrozil have increased 
the plasma concentrations of several statins,188,231-235 13,14,236-238 and OATP1B1 is 
involved in the hepatic uptake of (at least) pravastatin,239 cerivastatin,22 
rosuvastatin232 and atorvastatin.240 For example, the AUC of pravastatin, which 
has no significant CYP-mediated biotransformation, is increased 2–fold by 
gemfibrozil237 and more than 10-fold by cyclosporine.241 The similarities in the 
observed drug interactions of gemfibrozil and cyclosporine are probably caused 
by the interaction mechanism common to both, that is, inhibition of OATP1B1.  
The relative contributions of CYP and OATP1B1 inhibition in the gemfibrozil-
repaglinide and cyclosporine-repaglinide interactions are difficult to estimate. 
Inhibition of a single CYP enzyme by specific inhibitors, without an additional 
mechanism, has produced only moderate (<80%) increases in the AUC of 
repaglinide.8,9,12 Increases in repaglinide AUC, 2.4-fold increase by cyclosporine 
and 8.1-fold by gemfibrozil,9 are clearly of greater magnitude. In the case of 
cyclosporine, the component of OATP1B1 inhibition is probably more important 
than CYP3A4 inhibition, because cyclosporine is a weaker CYP3A4-inhibitor21 
than itraconazole207 or clarithromycin242 in vivo, which have increased 
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repaglinide AUC by <40%. Gemfibrozil (and its glucuronide conjugate) are avidly 
taken up into hepatocytes from circulation243,244 and the glucuronide conjugate is 
a mechanism-dependent inhibitor of CYP2C8,214,215 probably making gemfibrozil 
a more potent inhibitor of CYP2C8 than trimethoprim in vivo. However, based on 
the available findings, no firm conclusions can be made about the relative 
importance of inhibition of CYP2C8 and OATP1B1 in the gemfibrozil-repaglinide 
interaction.9  
2.3.4 Effect of rifampicin 
To date, three studies have been conducted to determine the effect of rifampicin 
on the pharmacokinetics of repaglinide. In all these studies, the rifampicin pre-
treatment dose was 600 mg once daily, administered for 5 to 7 days, and a 
single repaglinide dose was administered 0 to 24 h after the last rifampicin dose. 
When repaglinide was given together with or 1 h after the last rifampicin dose, a 
48% and 31% reduction in repaglinide AUC was seen, respectively. However, 
when repaglinide was administered 12.5 h or 24 h after the last rifampicin dose 
and a 57% and 80% reductions in repaglinide AUC, respectively, were seen.10-12  
Thus, rifampicin seems to act both as an inducer and inhibitor of repaglinide 
metabolism.11 In vitro results confirmed that rifampicin competitively inhibited 
CYP2C8, CYP3A4 and repaglinide metabolism in HLM (I). It appears that when 
the concentration of rifampicin in the body is high, it blunts its own inducing 
effect and only a modest effect on repaglinide AUC is seen. Greater reductions in 
repaglinide AUC are seen when only small (<10% of the dose after 12 h) or 
negligible (<1% after 24 h) amounts of rifampicin are left in the body.  
These findings affect the design of drug-drug interaction studies where rifampicin 
is used as an inducer of drug metabolism. The inhibitory effect of rifampicin 
could also influence the optimal dosing times of other drugs when they must be 
coadministered with rifampicin. If the inducing effect of rifampicin can be blunted 
even partially, by ingesting coadministered drugs soon after rifampicin, their 
bioavailability and therapeutic effect could be improved.  
2.3.5 Pharmacokinetic studies without observed interaction 
Bezafibrate, fenofibrate, montelukast, and pioglitazone had no effect on the 
pharmacokinetics of repaglinide in vivo. It appears that even though these drugs 
have been shown to inhibit CYP activity in vitro, they are not sufficiently potent 
CYP2C8 or CYP3A4 inhibitors to influence repaglinide metabolism in vivo, 
especially as their available concentration to inhibit the enzyme is low due to 
high plasma protein binding (>95% for all).178  
Concomitant treatment with CYP3A4 substrates simvastatin, nifedipine or oral 
contraceptive (ethinyloestradiol/levonorgestrel) has not significantly increased 
the AUC of repaglinide.2,12 Concomitant simvastatin, nifedipine, and cimetidine 
have increased repaglinide mean AUC slightly (by <20%), but the changes have 
not been statistically significant. It appears that these drugs are too weak 
CYP3A4 or CYP2C8 inhibitors to significantly influence repaglinide 
pharmacokinetics. 
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3 Clinical implications 
Drug-drug interactions are an important aspect of the treatment of type 2 
diabetes, because oral antidiabetic drugs often need to be combined with other 
drugs to treat concurrent diseases.154 Use of insulin secretion enhancers, such as 
repaglinide, carries a risk of hypoglycemia,1 and pharmacokinetic interactions 
leading to elevated drug concentrations can further increase the risk. There is 
considerable interindividual variation in the susceptibility to drug interactions, 
due to both genetic and environmental differences.49 Furthermore, the extent of 
drug interactions largely depends on the dosing and timing of administration of 
both the substrate and the inhibitor.49 
Based on studies II-VI, it can be concluded that bezafibrate, fenofibrate, 
montelukast, and pioglitazone do not affect repaglinide pharmacokinetics, but 
that coadministration of trimethoprim, telithromycin, or cyclosporine can 
increase repaglinide plasma concentrations. Repaglinide is susceptible to 
inhibition of CYP2C8, CYP3A4, or OATP1B1, and an increase its plasma 
concentrations can lead to markedly increased blood glucose-lowering effect and 
associated hypoglycaemia. When such inhibitor is started in patient receiving 
repaglinide, closer monitoring or blood glucose concentrations is advisable, and 
repaglinide dose may need to be reduced. Correspondingly, repaglinide dose 
may need to be raised when the inhibitor is discontinued.  
In the studies included in this thesis, a subclinical repaglinide dose was used, but 
the risk of hypoglycaemia is greater when higher repaglinide doses are used in 
the clinical practice. Simultaneous inhibition of CYP2C8, CYP3A4, and OATP1B1 
(by gemfibrozil and itraconazole) has synergistically increased the plasma 
concentrations and effects of repaglinide,9 and such synergism may also occur 
with other drug combinations, which increase repaglinide plasma concentrations 
through multiple interaction mechanisms.    
The prevalence of hypertriglyceridemia and low HDL cholesterol concentrations is 
twice as high in diabetics as in nondiabetics.245,246 Statins are widely used in 
diabetic patients, but fibrates are often chosen if the predominant lipid 
abnormality is hypertriglycederimia.154 The concomitant use of gemfibrozil and 
repaglinide is not recommended because of their potentially hazardous 
interaction. The present findings have important therapeutic consequences, as 
bezafibrate and fenofibrate can be used together with repaglinide due to the lack 
of interaction.  
Short-term use of antimicrobial agents is common, and a course of trimethoprim 
or telithromycin might be necessary in patients receiving repaglinide. 
Concomitant use of trimethoprim or telithromycin with repaglinide may increase 
the risk of hypoglycaemia, particularly when higher repaglinide doses are used in 
diabetic patients, and it is advisable to monitor blood glucose concentrations 
closely in such situations, and reduce repaglinide dosage if necessary.  
New-onset diabetes mellitus develops to 2-53% of renal transplant recipients,247 
and concomitant use of repaglinide and cyclosporine is a treatment option in this 
patient group.248 Simultaneous use of cyclosporine and repaglinide may increase 
the risk of hypoglycaemia particularly if higher cyclosporine and repaglinide 
doses are used. In a recent study of management of new-onset diabetes mellitus 




after renal transplantation, patients receiving cyclosporine and repaglinide 
showed better improvement in blood glucose concentrations than those receiving 
repaglinide and tacrolimus or sirolimus.248 Increased repaglinide concentrations 
may have contributed to the better treatment response in the cyclosporine 
group, but repaglinide concentrations were not monitored in that study. 
However, there was no difference in the required repaglinide dose, decrease in 
HbA1c levels, or incidence of hypoglycaemias, suggesting that the increase in 
repaglinide concentrations was moderate at most.249 However, close monitoring 
of blood glucose concentrations is necessary in this patient group. 
Combination of repaglinide and a glitazone can be used in diabetic patients,1 and  
the combination of repaglinide and pioglitazone has been shown to much more 
effective (1.8% mean reduction in HbA1c), than their respective monotherapies 
(repaglinide HbA1c -0.2%, pioglitazone +0.3%).20 The synergistic effect of 
pioglitazone-repaglinide combination therapy can be explained by a slowly 
developing pharmacodynamic interaction without a pharmacokinetic component, 
as pioglitazone does not increase repaglinide concentrations, and the two drugs 







C O N C L U S I O N S 
STUDY I CYP2C8 and CYP3A4 were of equal importance in the metabolism of 
therapeutic repaglinide concentrations in vitro, but their predicted contributions 
in vivo were variable and depended of the scaling approach used. Inhibition of 
CYP2C8 by parent gemfibrozil is unlikely to explain its interaction with 
repaglinide in vivo, because it is only a moderately potent inhibitor of CYP2C8 
and repaglinide metabolism in vitro. Rifampicin competitively inhibited CYP2C8, 
CYP3A4 and repaglinide metabolism in vitro, which presumably counteracts its 
own inducing properties in vivo. 
STUDY II Bezafibrate and fenofibrate did not increase the plasma concentrations 
or blood glucose-lowering effect of repaglinide. This lack of interaction is clearly 
in contrast with the strong interaction of gemfibrozil with repaglinide, and 
suggests that bezafibrate or fenofibrate can be used together with repaglinide 
with no dosage modifications. 
STUDY III Trimethoprim raised the plasma concentrations of repaglinide, most 
likely by inhibiting its CYP2C8-mediated biotransformation. Although no 
significant increase in the blood glucose-lowering effect of repaglinide was seen 
in this study, concomitant use of repaglinide and trimethoprim may increase the 
risk of hypoglycaemia, particularly if higher repaglinide doses are used. 
STUDY IV Cyclosporine considerably raised the plasma concentrations of 
repaglinide, probably by inhibiting both the CYP3A4-catalysed metabolism and 
the OATP1B1-mediated hepatic uptake of repaglinide. Concomitant use of 
repaglinide and cyclosporine may increase the risk of hypoglycaemia, particularly 
if higher cyclosporine and repaglinide doses are used.  
STUDY V Telithromycin increased the plasma concentrations and blood glucose-
lowering effect of repaglinide, probably by inhibiting its CYP3A4-catalysed 
biotransformation. The possibility of an increased risk of hypoglycaemia should 
be considered when the two drugs are used concomitantly. Montelukast had no 
effect on the pharmacokinetics of repaglinide, suggesting that it does not 
significantly inhibit CYP2C8 in vivo, assumably due to its extensive binding to 
plasma proteins.  
STUDY VI Pioglitazone did not increase the plasma concentrations of repaglinide. 
This indicates that pioglitazone does not significantly inhibit CYP2C8 or CYP3A4 
in vivo, probably due to its extensive plasma protein binding. The synergistic 
effect of pioglitazone and repaglinide seen in patients with type 2 diabetes is 
unlikely to be caused by inhibition of repaglinide metabolism by pioglitazone, and 
can be explained by a pure pharmacodynamic interaction. 
GENERAL These findings underline the importance of carrying out drug interaction 
studies in humans to confirm predictions based on in vitro data, and highlight 
the significance of incorporating plasma protein binding to predictions of CYP 
inhibition based-interactions. The results emphasise the importance of 
transporter inhibition and genetic variation of drug-metabolising enzymes and 
drug transporters as factors affecting the magnitude of drug-drug interactions.  
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